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ABSTRACT 
 
Hypertension is one of major challenges for global health policy. Effective 
control of blood pressure is essential for alleviation of the burden of disease, while the 
current global situation of blood pressure control is far from ideal. Public health 
interventions for hypertension classically have two dimensions: primary prevention in 
communities, and diagnosis and treatment in clinical practice for secondary prevention. 
From the standpoints of the public and clinical practice, this thesis studied two 
important issues related to the management of hypertension in the population of Japan, 
in order to provide useful information for health policy. 
The first study examined the relationships between the observed reduction in 
mean systolic blood pressure (SBP) in Japan between 1986 and 2002 and the change in 
the use of antihypertensive treatment and lifestyle-related factors. A nationally 
representative sample of 90,554 men and 101,903 women aged 20 years and over was 
obtained from pooled data of annual cross-sectional surveys in Japan during 1986–2002. 
A two-stage regression model with an instrumental variable was employed to 
investigate the association between SBP and antihypertensive medication and lifestyle 
factors, including body mass index (BMI), physical activity, alcohol consumption, 
cigarette smoking, and dietary sodium intake. In the surveys, regular exercise was 
defined as exercise for more than 30 minutes at a time more than twice a week for over 
1 year. Current smoking was defined as either daily or occasional cigarette use. Current 
drinking was defined as an intake of more than one standard cup of Japanese sake, one 
large bottle of regular beer, or one double measure of whisky at a time more than three 
times a week. Changes in mean predicted SBP in each sex and age group between 1986 
  iv
and 2002 were decomposed into the respective contributions of these explanatory 
variables. Age-specific means of predicted SBP declined during this period by 1.8 (95% 
confidence interval, CI: 1.2–2.5) to 3.0 (95% CI: 2.4–3.6) mmHg in men and 3.7 (95% 
CI: 3.4–4.1) to 5.1 (95%CI: 4.5–5.7) mmHg in women. These reductions were partly 
explained by the increased use of medications across all sex and age groups and 
decreased mean BMI in women in their 30s and 40s. The contributions of treatment 
effects increased with age. Elevated mean BMI in men and elderly women offset part of 
the decline of their mean SBP. These results indicate that declining mean SBP was 
partly attributable to the increased use of antihypertensive medications, especially in the 
older population, and lowered mean body mass index in young women. However, a 
substantial part of the decline is left unexplained and needs to be investigated further. A 
still greater decline in SBP would be expected through improvements in body weight 
management, salt and alcohol intake, and treatment and control of hypertension. 
The second study assessed clinic physicians’ awareness of the first official 
clinical guideline on the management of hypertension in Japan (JSH 2000) and their 
adherence to the recommendations of this guideline. Data were obtained from two 
postal questionnaire surveys conducted in 2000 and 2004 on a nationally representative 
sample of clinic physicians who engaged in general internal medicine. The sample size 
was 896 in 2000 and 1,425 in 2004. Recognition rates of JSH 2000 were 63.1% (n=822) 
before its announcement in 2000 and 94.4% (n=1,400) in 2004. Rates of access, 
familiarity, and utilization of the guidelines were 87.0, 81.5, and 68.6%, respectively, in 
2004. As for major management strategies for low-risk hypertension: in 2000, for 
patients with 140–149/90–94 mmHg, 81.5% of 812 respondents performed lifestyle 
modification, and 11.2% prescribed medicines, whereas for patients with 150–159/95–
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99 mmHg, 71.7% of 807 respondents prescribed medicines, and 24.3% conducted 
lifestyle modification; in 2004, 85.5% of 1,384 respondents conducted lifestyle 
modification, 22.6% prescribed medicines, 2.5% referred patients to other facilities, and 
6.4% did nothing. In 2004, 68.9% of 1,388 respondents agreed with the new definition 
of hypertension, whereas 17.1% preferred 160/95 mmHg. The choice of the old criteria 
was significantly associated with respondents’ age (p<0.05), the number of hypertensive 
outpatients in daily patient load (p<0.05), and awareness of the guideline 
recommendations. These findings showed that there had been a substantial 
improvement in clinic physicians’ awareness of, and adherence to, this official guideline 
during the four years since its announcement in 2000. Nevertheless, a considerable 
number of physicians still preferred to employ the old diagnostic criteria for 
hypertension in 2004. The management of hypertension would be further enhanced 
through strengthening the dissemination of the revised guidelines to older physicians or 
those who see relatively few hypertensive outpatients and also by supporting 
physicians’ comprehension and implementation of its recommendations in practice. 
Although the control of blood pressure in the community and clinical practice 
has improved over time, there is still substantial room for improvement. Diverse 
perspectives in the community and clinical practice are necessary to resume or 
accelerate the progress in the management of hypertension in Japan. It is crucial to 
reinforce policies that encourage awareness of the public and medical practitioners 
about effectiveness of evidence-based medicine for prevention and treatment of high 
blood pressure, in particular regarding modification of behavioral risk factors and early 
detection and adequate treatment of hypertension. 
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Two methodological directions are proposed for future research on evaluation of 
interventions for the management of high blood pressure: 1) the extensive collection of 
key information and the refinement of measurement methods of blood pressure in 
household surveys; and 2) the introduction of multidisciplinary approaches for the 
analysis of health survey data. Population health metrics and evaluation will play a 
pivotal role in strengthening national health information systems to share powerful 
evidence on outcomes of Japanese health policies and programs with the international 
community of policymakers and academics. Interactive dialogues would eventually help 
us learn what is essential in future health policies for the effective control of population 
blood pressure in Japan. 
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CHAPTER 1 
Introduction 
 
 
Hypertension is one of major challenges for global health policy. A quarter of 
the adult population in the world had high blood pressure in 2000, and the hypertensive 
population is predicted to reach 1.5 billion by 2025 (Kearney et al. 2005). As one of 
leading risk factors for cardiovascular and renal diseases (Lewington, Clarke, Qizilbash, 
Peto and Collins 2002; Vasan et al. 2001), hypertension contributed to a half of 
premature mortality and disability from stroke and ischemic heart diseases and 
accounted for 14% and 6% of deaths and disability, respectively, from all causes 
worldwide in 2001 (Lawes, Vander Hoorn and Rodgers 2008). Moreover, elevated 
blood pressure is no longer an issue only in economically developed nations, but it has 
been becoming increasingly influential in developing countries: more than 80 percent of 
the disease burden attributable to high blood pressure occurred in low-income and 
middle-income regions in that year (Ezzati et al. 2006; Lawes et al. 2008). 
Effective control of blood pressure is essential for alleviation of the burden of 
disease, while the current global situation of blood pressure control is far from ideal. 
For example, blood pressure is controlled with antihypertensive medication among only 
28% and 37% of adults having hypertension in England and the USA, respectively 
(Falaschetti, Chaudhury, Mindell and Poulter 2009; Ong, Cheung, Man, Lau and Lam 
2007). The control rate is even worse in low-income and middle-income countries — 
for instance, it is 5% in China (Wu et al. 2008), 6% in Iran (Esteghamati et al. 2008), 
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and 8% in Turkey (Altun et al. 2005). These figures suggest that present health policies 
are not optimal and need be revised to enhance blood pressure control at the population 
level. 
Public health interventions for blood pressure control classically have two 
dimensions. One is primary prevention of hypertension in communities. The 
population-based and intensive approaches are available to promote healthy lifestyles 
and maintain adequate blood pressure in the population group having normal blood 
pressure. The population-based approach aims to shift the whole distribution of blood 
pressure downward in the general population, while the intensive approach focuses on 
individuals at risk for hypertension to achieve a greater reduction in blood pressure at 
the population level (Whelton et al. 2002a). Both of these preventive approaches 
address healthy lifestyles through measures that have a proven efficacy for the reduction 
of blood pressure in the normotensive population, such as weight loss (Neter, Stam, 
Kok, Grobbee and Geleijnse 2003), decreased intake of dietary sodium (Dickinson and 
Havas 2007), moderation of alcohol consumption (Xin et al. 2001), increased physical 
activity (Whelton, Chin, Xin and He 2002b), potassium supplementation (Whelton et al. 
1997), and the modification of eating patterns (Sacks et al. 2001). 
Another dimension of public health measures for blood pressure control is 
diagnosis and treatment of hypertension for secondary prevention. Early detection of 
elevated blood pressure and prescription of appropriate therapies are crucial to minimize 
the risk of subsequent cardiovascular and renal events. Identification of hypertensive 
patients requires regular monitoring of blood pressure of individuals in the community, 
because the condition is asymptomatic until it becomes severe. It is, therefore, essential 
to motivate individuals to access health services for blood pressure screening, such as 
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health checkups and to use devices for self-monitoring. Moreover, clinical practice is 
another important factor for the diagnosis and treatment of hypertension. As a part of 
the efforts to help physicians improve their clinical practice, clinical guidelines for 
management of hypertension have been published in a number of countries. Based on 
the best available scientific evidence and situations of individual countries, leading 
experts have built consensus on procedures of diagnosis and treatment of hypertension 
(Chobanian et al. 2003; Mancia et al. 2007; McAlister et al. 2009; National Heart 
Foundation of Australia 2009; Ogihara et al. 2009; Williams et al. 2004; World Health 
Organization 2003). The understanding and adherence of clinic physicians to evidence-
based medicine is the key to achieving the control of blood pressure of the hypertensive 
group. 
In Japan, average blood pressure started decreasing in the mid-1960s, which 
preceded the declining trend of mortality from stroke by a decade (Ueshima, Tatara, 
Asakura and Okamoto 1987). The reduction in stroke mortality was then accompanied 
by the extension of life expectancy among the Japanese population so that it became 
among the highest in the world. Despite the improvement in mean population blood 
pressure, the management of hypertension is not yet sufficient in Japan: in 2006, the 
prevalence of high blood pressure in the adult population was around 40%, and only 
half of the hypertensive group took antihypertensive medications on a daily basis 
(MHLW 2009a). These figures suggest that there is still substantial room for 
improvement in the management of hypertension in this country. Understanding is still 
lacking, concerning which factors should be prioritized when it comes to enhancing the 
control of blood pressure at the population level. The management of hypertension 
needs to be comprehensively evaluated in the contexts of both communities and clinical 
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practice, so that policymakers leverage scientific evidence in prioritizing issues for the 
control of blood pressure of the whole population. 
This thesis assembles two studies to discuss the control of blood pressure in the 
population of Japan. Chapter 2 investigates trends in mean systolic blood pressure 
(SBP) between the late 1980s and the early 2000s. The study assesses how the SBP of 
individuals is determined by various lifestyle-related factors and pharmacological 
treatment and how much of the reduction in mean SBP is explained by improvements in 
these factors through primary and secondary prevention. It then suggests which factors 
should be prioritized in health policies to reinforce the control of blood pressure at the 
population level. In addition, this is the first study to apply an econometric approach for 
the quantification of treatment effects from cross-sectional surveys on nationally 
representative samples in Japan. It provides an innovative example that will create new 
possibilities for public health research in this country. 
Chapter 3 focuses on the clinical aspects of blood pressure control to examine 
the attitudes of clinic physicians toward evidence-based medicine on the detection and 
treatment of hypertension in Japan. The Japanese Society of Hypertension announced 
their first official clinical guidelines for the management of hypertension in 2000 (JSH 
2000), and revised editions were published in 2004 and 2009. Using physician surveys 
conducted in 2000 and 2004, this study assesses the change in medical practitioners’ 
awareness of and adherence to the recommendations of JSH 2000, in order to explore 
whether the guidelines succeeded in improving clinical practice for the effective control 
of blood pressure. The study provides useful information to support the interpretation of 
clinical factors concerning the management of hypertension, although it does not reveal 
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anything about the direct relationship between their adherence to the guideline and the 
control of blood pressure. 
Based on the perspectives of the community and clinical practice, Chapter 4 
integrates the major findings from the preceding two chapters in order to discuss the 
achievements and future challenges of public health policies in promoting the efforts 
toward the effective control of blood pressure in the population of Japan. The thesis 
then concludes with future methodological directions for population health research in 
relation to the management of hypertension in this country. 
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CHAPTER 2 
Understanding the decline of mean systolic blood pressure in Japan:  
an analysis of pooled data from the National Nutrition Survey,  
1986–2002 
 
 
2.1 Background and objectives 
 
The global trend of hypertension has been worsening. The estimated global 
prevalence of hypertension was more than 25% among adults in the year 2000 and it is 
projected to rise, especially in developing countries, during the first quarter of the 21st 
century (Kearney et al. 2005). It is also noteworthy that population average SBP in the 
USA decreased during the 1970s and 1980s, but the trend has stagnated since the 1990s 
(Burt et al. 1995; Hajjar and Kotchen 2003; Ong et al. 2007). 
Control of SBP is an important public health issue because elevated SBP is one 
of the major independent risk factors for cardiovascular disease (CVD) (He and 
Whelton 1999; Lawes, Bennett, Lewington and Rodgers 2002; Lawes, Bennett, Feigin 
and Rodgers 2004a). CVD is a leading contributor to the global burden of disease, 
accounting for 28% of 50 million deaths and 13% of 1.4 billion disability-adjusted life 
years in 2001 (Mathers, Lopez, Murray, Ezzati and Jamison 2006). Several prospective 
cohort studies revealed that lower SBP at baseline is associated with reduced mortality 
from and incidence of CVD (Lawes et al. 2002; Lawes et al. 2004a; Okayama, 
Kadowaki, Okamura, Hayakawa and Ueshima 2006). It has been reported that even a 
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decline of SBP at baseline by 2 mmHg is associated with a decrease of 16-year 
mortality from CVD by 5% (Stamler 1997). Effective control of SBP is thus essential 
for improving population health. 
A declining trend of average SBP in the general population has been observed in 
a number of regions and countries including Japan (Burt et al. 1995; Kuulasmaa et al. 
2000; Okayama et al. 1993; Sakata and Labarthe 1996; Sproston and Primatesta 2004; 
Ueshima et al. 1987). Understanding why it has been decreasing in these populations is 
crucial for developing effective public health policies in individual countries as well as 
for global health policies for blood pressure control. Although population-wide and 
personal interventions might have been successful, the factors that actually contributed 
to the decline of mean SBP have not been investigated yet, largely due to the lack of 
longitudinal data based on a nationally representative sample. Two previous studies, 
demonstrating the downward shift of the distribution of SBP in the population over time, 
suggested that the changes in population-wide behaviors and environmental conditions 
made a larger contribution to the trend than improved treatments (Goff Jr, Howard, 
Russell and Labarthe 2001; Tunstall-Pedoe, Connaghan, Woodward, Tolonen and 
Kuulasmaa 2006). However, the nature of the cross-sectional survey data that were used 
in these studies still precluded further quantification of the contributions of individual 
factors, in particular the effects of antihypertensive medications. 
Japan has experienced a remarkable reduction in population mean SBP since the 
late 1960s (Japanese Society of Hypertension 2006; Okayama et al. 1993; Sakata and 
Labarthe 1996; Ueshima et al. 1987). A past ecological study attributed the decline of 
mean SBP between 1965 and 1980 to the increased number of CVD outpatients per unit 
of population, which was used as a proxy of the treatment rate of CVD (Ueshima et al. 
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1987). However, so far no one has examined in depth why mean SBP further decreased 
since the 1980s in Japanese adults, although individual-level data on SBP and the use of 
antihypertensive medications have been accumulated and are electronically available for 
scientific studies. 
The objective of this study was to explore the factors linked to SBP of 
individuals and assess contributions of the changes in lifestyle-related factors as well as 
the use of antihypertensive medications to the decline of mean SBP in the adult 
population of Japan. A statistical model was applied to overcome the inherent problems 
in estimating treatment effects from cross-sectional data, taking full advantage of pooled 
data of individual records from annual national surveys that were conducted between 
the mid 1980s and the early 2000s. 
 
2.2 Methods 
 
Data sources 
This study used a pooled dataset of individual records from the National 
Nutrition Surveys (NNS) between 1986 and 2002. The NNS is a cross-sectional 
interview and examination survey conducted on a nationally representative sample 
every November by the Ministry of Health (the name was changed to the Ministry of 
Health, Labour and Welfare [MHLW] in 2001). This study period was adopted because 
the survey had started collecting data on antihypertensive medication in 1986 and micro 
data were electronically available up to the survey in 2002 when the research was 
carried out. 
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The NNS aims at obtaining basic data on anthropometry, nutritional intake and 
diet, and lifestyles to establish measures for nationwide health promotion (MHLW 
2002). The methods of the NNS have been described in detail elsewhere (Katanoda and 
Matsumura 2002). To summarize, eligible respondents included all residents aged 1 
year and older in 300 census tracts that were randomly selected from around 900,000 
census tracts. Response rates of the NNS were estimated to be 60–70% (Yoshiike et al. 
1998), and the sample was considered to be representative of the Japanese population 
(Katanoda, Nitta, Hayashi and Matsumura 2005). 
In the NNS, all household members were asked to participate in a physical 
examination at a local community center near their residence on a specific day during 
the survey period. Certified professionals such as medical doctors, public health nurses 
and registered nurses measured blood pressure in the right upper arm of seated persons 
after 5 minutes’ rest, using a Riva-Rocci mercury manometer and no specification on 
cuff size. Systolic and diastolic blood pressures were recorded once until 1999 and 
twice starting in 2000. The present study used only the first measurement of SBP to 
ensure consistency of measurements throughout the period of analysis. Moreover, using 
a spring scale and a stadiometer, public health nurses measured the height and weight of 
participants wearing light clothes and no shoes. Body mass index (BMI) was calculated 
as body weight in kilograms divided by the square of body height in meters. 
At the site of the physical examination, a medical doctor questioned participants 
aged 20 years and over about their current use of antihypertensive medications, smoking 
and drinking habits, and physical activity. These variables were qualitative, and survey 
participants answered using dichotomous or multichotomous response categories. In the 
NNS, individuals were considered to have regular exercise if they reported exercising 
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for more than 30 minutes at a time more than twice a week for over 1 year; to be current 
smokers if they reported smoking daily or occasionally; and to be current drinkers if 
they self-reported consuming more than one standard cup of Japanese sake, one large 
bottle of regular beer, or one double measure of whisky at a time more than three times 
a week (MHLW 2002). 
Nutritional intake was surveyed at households using a self-administered 
questionnaire. Until 1994, nutrition intake was recorded at the household level only, and 
household representatives weighed and recorded the quantity of each food item 
consumed by the household for three consecutive days. The survey on nutrition intake 
of individuals started in 1995, while the study period was shortened to one day. The 
present analysis used aggregated data on daily salt intake per capita at the prefecture 
level in each survey year as a reference for individual salt intake, because this was the 
best available data on this item between 1986 and 1994. Prefectures are local governing 
units, and there are 47 prefectures in Japan. This variable was obtained for the 1986–
1994 surveys from the Health and Nutrition Information Infrastructure Database based 
on the NNS (National Institute of Health and Nutrition 2007), and for the 1995–2002 
surveys it was aggregated from the micro data. 
Missing values on the variables included in the present study were imputed, and 
five imputed datasets were created for analysis by using Amelia II: A Program for 
Missing Data version 1.1–23 (Honaker, King and Blackwell 2007). 
 
Statistical analysis 
All analyses were performed separately by sex, because trends in the key 
variables were different between sexes. Subjects were included in the analyses if they 
  11
were over 20 years of age, neither pregnant nor breastfeeding. Age-adjusted means of 
SBP with 95% confidence intervals (CI) were estimated annually between 1986 and 
2002 to study the trends in mean SBP during this period. 
A couple of issues had to be solved in the specification of a statistical model on 
the association between SBP and antihypertensive treatment of the general population. 
One was reverse causation: in the observational data, people who had high blood 
pressure were more likely to take antihypertensive medications. A standard, ordinary 
least squares regression of blood pressures on antihypertensive medication would 
consequently yield a positive coefficient, which was contrary to the expected beneficial 
treatment effects (i.e. the inverse association). The other issue was selection bias: the 
assignment of the pharmacological treatment was not random in this non-experimental 
survey data. The treatment variable would be correlated with the error term if observed 
or unobserved covariates were not equally distributed between the treated and the 
untreated in the general population. 
In order to address these challenges in estimating treatment effects from the 
observational data, this study employed the method of instrumental variables (Angrist, 
Imbens and Rubin 1996). The original idea of instrumental variables dates back to a 
study on supply and demand curves in economics during the 1910s (Stock and Trebbi 
2003), and it has been applied in a number of studies in medical and public health fields 
since at least the late 1980s (Eisenberg and Quinn 2006; Ettner 1996; McClellan, 
McNeil and Newhouse 1994; Permutt and Hebel 1989; Wang et al. 2005). The 
instrumental variable approach aims to obtain consistent estimates from observational 
data when an explanatory variable in the equation is correlated with the error term. This 
correlation largely occurs in four situations: 1) the outcome variable has an influence on 
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the explanatory variable (reverse causation); 2) some relevant explanatory variables are 
not observed and are excluded from the model (omitted variable bias); 3) the treatment 
group is not selected randomly (selection bias); and 4) some of the explanatory 
variables are measured with errors (measurement error). 
A valid instrumental variable is assumed to meet at least two conditions. First, it 
has no correlation with the error term in the equation of an outcome variable either 
directly or indirectly via other covariates. Put differently, the valid instrumental variable 
is exogenous and has no effect on the outcome variable (the exogeneity condition). 
Second, it has at least some correlation with the endogenous treatment variable. In other 
words, the instrumental variable is relevant to the exposure variable to some extent (the 
relevance condition). Figure 2.1 illustrates the relationships between the instrumental 
variable, the treatment variable, the outcome variable, and other covariates in the two-
stage regression. In the first-stage regression, the exogenous instrumental variable 
induces random variation in the endogenous treatment variable across observations, so 
that the second-stage regression yields consistent estimates on the association between 
the outcome variable and the randomized, predicted values of the treatment variable. 
The instrumental variable used in the present analysis was crude coverage of 
antihypertensive medication at the prefecture level. It was assumed that the proportion 
of individuals with hypertension who were receiving treatment in an area where they 
reside influences the likelihood of their taking blood pressure lowering drugs but does 
not directly affect their SBP. For each of 94 groups defined by sex and prefecture of 
residence, the instrumental variable was computed as a single average across the period 
from 1986 to 2002. Annual averages were not used because denominators, i.e. the 
hypertensive group, were not large enough to derive stable values in some cells. In this 
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study, individuals were considered to be hypertensive if they had an SBP of 140 mmHg 
or higher or reported daily use of antihypertensive medications. Although a diastolic 
blood pressure of 90 mmHg or over is also considered in the widely used definition of 
hypertension (Chobanian et al. 2003), only SBP was used in this study for two reasons: 
the first was simplification of the analysis, and the second was that SBP had been found 
to be a better predictor of cardiovascular risks than diastolic blood pressures (Lawes et 
al. 2004b). Treatment was defined as the self-reported daily use of antihypertensive 
medications. 
In the first stage of the two-stage regression, the probability of being on 
treatment was predicted for each individual, using the following logistic model: 
MEDi = α1 + β1COVi + γ1Xi + ε1i 
where MED was a binary variable for taking antihypertensive medication; COV was the 
instrumental variable; X was the matrix of other covariates; ε is an error term; 1 
signified the first equation; and i indexed observations. The covariates included an 
interaction between BMI and age, cigarette smoking, alcohol drinking, regular exercise, 
daily salt intake, and survey year. Table 2.1 lists recoding and analytic strategies for 
these variables included in the model. 
In the second stage of the model, ordinary least squares regression was used to 
study the SBP of individuals as a function of the predicted probability of being treated 
and all independent variables used in the first stage except for the instrumental variable. 
The equation was specified as follows: 
SBPi = α2 + β2Prob(MED)i + γ2Xi + ε2i 
where Prob(MED) was the predicted probability of taking antihypertensive medication 
daily; 2 signified the second equation; and X was defined as the first equation. 
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Using regression coefficients estimated from the second-stage regression, the 
change in mean predicted SBP between the beginning and end of the study period, i.e. 
1986 and 2002, was decomposed into contributions of the explanatory variables by sex 
and age group. For each explanatory variable, adjusted linear predictions of SBP in 
1986 and 2002 were computed, setting other variables to their means. These adjusted 
means, standard errors, and sample sizes were then used to calculate means and 95% CI 
for the differences noted between the two years. 
All analyses were conducted with Stata/MP version 10.1 (StataCorp LP, College 
Station, TX, USA). Means and standard errors calculated from the five imputed datasets 
were combined following King and colleagues (King, Honaker, Joseph and Scheve 
2001). The t-test was performed to test the null hypothesis of no difference in age-
specific or age-standardized means between groups. P-values less than 0.05 were 
considered to indicate statistical significance. CLARIFY 2.0 (Harvard University, 
Cambridge, MA, USA) was used to simulate and combine parameters of regression 
equations from the imputed datasets (King, Tomz and Wittenberg 2000; Tomz, 
Wittenberg and King 2001). For age-standardization, the total population by 5-year age 
groups was obtained from the 2000 Population Census of Japan (Ministry of Internal 
Affairs and Communications 2001). 
 
2.3 Results 
 
Basic characteristics of the study population 
A sample of 192,457 was obtained for analysis (90,554 men and 101,903 
women), after 64,722 respondents younger than 20 years old and 2,671 pregnant or 
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breastfeeding women were excluded from a total of 259,850 respondents in the pooled 
dataset. Table 2.2 summarizes age-standardized means and 95% CI of the key variables 
by sex in 1986 and 2002. The age-standardized mean BMI increased from 22.5 kg/m2 
(95% CI: 22.5–22.6 kg/m2) to 23.3 kg/m2 (95% CI: 23.2–23.4 kg/m2) in men (p<0.001), 
while it stayed at 22.4 kg/m2 in women (p=0.652). The age-standardized prevalence of 
regular exercise increased from 21.5% (95% CI: 20.5–22.6%) to 32.2% (95% CI: 30.8–
33.6%) in men (p<0.001) and from 14.9% (95% CI: 14.0–15.7%) to 29.0% (95% CI: 
27.7–30.3%) in women (p<0.001). The age-standardized prevalence of current smokers 
decreased in men from 55.1% (95% CI: 53.9–56.4%) to 43.9% (95% CI: 42.4–45.4%, 
p<0.001), whereas it increased in women from 9.3% (95% CI: 8.6–10.0%) to 12.7% 
(95% CI: 11.7–13.7%, p<0.001). The age-standardized prevalence of current drinkers 
did not change in men, staying around 49% (p=0.718), while it rose in women from 
7.0% (95% CI: 6.4–7.6%) to 12.6% (95% CI: 11.6–13.6%, p<0.001). Daily salt intake 
on average slightly decreased from 12.1 grams to 11.8 and 11.7 grams in men and 
women, respectively (p<0.001 for each sex). 
 
Trends in mean systolic blood pressure and prevalence of hypertension 
Figure 2.2 illustrates the trends in age-standardized mean SBP by sex between 
1986 and 2002. It decreased in men from 135.6 mmHg (95% CI: 135.2–136.1 mmHg) 
to 133.0 mmHg (95% CI: 132.5–133.6 mmHg, p<0.001) and in women from 132.3 
mmHg (95% CI: 131.8–132.7 mmHg) to 127.8 mmHg (95% CI: 127.3–128.3 mmHg, 
p<0.001). Moreover, age-standardized mean SBP was, as expected, substantially higher 
in the treated group than in the untreated group in both sexes (p<0.001 for each sex; 
Table 2.3). This confirms the existence of simultaneous causality, or endogeneity, in the 
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data. Furthermore, as Table 2.4 shows, there was no difference in age-standardized 
mean SBP across quintiles of treatment coverage by prefecture (for the difference in 
mean SBP between the first and fifth quintiles, p=0.304 in men and p=0.391 in women). 
This indicates that the proposed instrumental variable satisfies the exogeneity condition 
of a valid instrumental variable. 
Table 2.2 shows that the age-standardized prevalence of hypertension 
significantly reduced by 3 percentage points in women (38.3% [95% CI: 37.4–39.3%] 
in 1986 and 35.3% [95% CI: 34.1–36.4%] in 2002, p=0.004), while the decrease was 
not significant in men (43.7% [95% CI: 42.5–44.8%] in 1986 and 42.9% [95% CI: 
41.6–44.2%] in 2002, p=0.529). These trends in the prevalence of hypertension are not 
in the same direction with those of mean blood pressure, because the definition of 
hypertension covers not only SBP but also treatment status in this study. The change in 
the prevalence rates is equivalent to a sum of changes in the prevalence of treated 
hypertension and that of untreated hypertension. In women, the prevalence of untreated 
hypertension decreased by 6 percentage points (95% CI: 5–7 percentage points, 
p<0.001), while the prevalence of treated hypertension increased by 3 percentage points 
(95% CI: 2–3 percentage points, p<0.001). In men, the two canceled each other—the 
prevalence of treated hypertension rose by 5 percentage points (95% CI: 3–6 percentage 
points, p<0.001), whereas the prevalence of untreated hypertension reduced by 5 
percentage points (95% CI: 4–7 percentage points, p<0.001). 
Among the hypertensive group, the age-standardized coverage of 
antihypertensive medication increased in both sexes to reach 39.7% (95% CI: 36.9–
42.6%, p<0.001) in men and 48.0% (95%CI: 44.3–51.7%, p=0.002) in women in 2002. 
The age-standardized rate of controlled SBP rose in both sexes, although it remained at 
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a low level of 20.5% (95% CI: 17.9–23.1%, p<0.001) in men and 27.2% (95% CI: 
23.7–30.8%, p<0.001) in women in 2002 (Table 2.2). 
 
Factors relating to individual systolic blood pressure 
Table 2.5 provides the summary of the instrumental variable, i.e. the proportion 
of hypertensive patients who were on antihypertensive medication by sex and prefecture. 
It ranged between 0.289 (95% CI: 0.256–0.325) in Kumamoto and 0.411 (95% CI: 
0.366–0.458) in Akita among men and between 0.331 (95% CI: 0.288–0.377) in 
Kagawa and 0.521 (95% CI: 0.476–0.566) in Akita among women. 
In the first-stage logistic regression, the individual use of blood pressure 
lowering drugs was significantly and positively associated with this instrumental 
variable in both sexes (odds ratio, OR: 47.5, 95% CI: 22.5–100.8, p<0.001 in men; OR: 
16.1, 95% CI, 8.9–29.2, p<0.001 in women) (Table 2.6). This means that the variable 
meets the relevance condition of a valid instrumental variable. The median of predicted 
probabilities of taking medications was 0.11 (range: 0.02–0.70) in men and 0.10 (range: 
0.02–0.92) in women. 
In the second-stage regression of SBP, individual SBP had a significant inverse 
association with the probability of taking medication, indicating that an increase in the 
likelihood of being treated by 10 percentage points was accompanied by a reduction of 
individual SBP by 2.05 mmHg (95% CI: 1.43–2.67, p<0.001) and 3.25 mmHg (95% CI: 
2.28–4.22, p<0.001) in men and women, respectively (Table 2.7). All other explanatory 
variables were significantly associated with SBP in both sexes, except regular exercise 
(b=-0.35, 95% CI: -0.79–0.06, p=0.085) and cigarette smoking (b=0.38, 95% CI: -0.20–
0.96, p=0.186) in women. In men, the association of regular exercise with SBP (b=-0.56, 
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95% CI: -0.95 to -0.18, p=0.007) was substantially smaller in the absolute term than that 
of alcohol drinking (b=3.17, 95% CI: 2.92–3.42, p<0.001), and the association of 
cigarette smoking with SBP was negligible (b=0.39, 95% CI: 0.00–0.78, p=0.048). The 
association of alcohol drinking with SBP in women was not so pronounced as that in 
men but was still substantial (b=2.41, 95% CI: 1.93–2.88, p<0.001). Daily salt intake 
had a significant positive association with SBP in both sexes (in men, b=0.43, 95% CI: 
0.25–0.61, p<0.001; in women, b=0.44, 95% CI: 0.29–0.59, p<0.001). 
The two-way interactions between age groups and BMI had overall statistically 
significant associations with SBP in both sexes. The coefficients of BMI showed a 
positive association with SBP in the reference age group, that is, people aged 20 to 29 
years. In this group, a one unit increase in BMI was significantly associated with an 
increase of SBP by 1.36 mmHg (95% CI: 1.20–1.52, p<0.001) and 1.29 mmHg (95% 
CI: 1.18–1.40, p<0.001) in men and women, respectively. Moreover, the coefficients of 
age groups indicated fixed effects of age on SBP with reference to the constant terms, 
that is, 86.1 mmHg (95% CI: 81.3–90.8 mmHg, p<0.001) in men and 83.3 mmHg (95% 
CI: 80.6–85.9 mmHg, p<0.001) in women, respectively. The age effect was statistically 
significant in men over 40 years of age and in women over 50 years of age. Finally, the 
coefficients of the product of BMI and age showed an additional change in SBP with 
one unit increase of BMI in each age group. This interaction effect was statistically 
significant in men aged between 55 and 69 years and in women over 35 years of age. 
The coefficients of the indicator variables of survey years represent the fixed 
effects of survey years that were not accounted for by other explanatory variables in the 
model. They were not statistically significant until 1990 in men and 1989 in women. 
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The unexplained part was the largest in 2000 of all years at -2.90 (95% CI: -3.87 to -
1.92, p<0.001) in men and -3.69 (95% CI: -4.50 to -2.89, p<0.001) in women. 
 
Decomposition of the decline in mean systolic blood pressure 
Table 2.8 provides the age-specific means of SBP predicted from the regression 
model, by sex and age group in 1986 and 2002. The means declined in all age groups in 
both sexes by 1.8 (95% CI: 1.2–2.5) to 3.0 (95% CI: 2.4–3.6) mmHg in men and 3.7 
(95% CI: 3.4–4.1) to 5.1 (95% CI: 4.5–5.7) mmHg in women. The difference in means 
between 1986 and 2002 was statistically significant across all sex and age groups 
(p<0.001). 
The change in age-specific mean SBP by sex between 1986 and 2002 was 
decomposed into contributions of the explanatory variables (Figure 2.3). An increased 
mean probability of taking antihypertensive medications made the largest contribution 
of all independent variables included in the model, except in young women. Among 
men the effect size ranged from -0.29 mmHg (95% CI: -0.31 to -0.27 mmHg) to -1.93 
mmHg (95% CI: -2.19 to -1.68 mmHg) in the 20–29 year and 70–74 year age groups, 
respectively, and among women from -0.22 mmHg (95% CI: -0.24 to -0.20 mmHg) to -
2.46 mmHg (95% CI: -2.90 to -2.03 mmHg) in the 30–34 year and 70–74 year age 
groups, respectively. The contribution of treatment increased with age in both sexes, 
reflecting the larger increase in the probability of being treated among older adults 
(Table 2.9). 
The contributions of BMI to the decline of mean SBP varied by sex and age, 
because of differences in the direction of change in mean BMI (Table 2.9). Mean BMI 
significantly decreased in women in their 30s and 40s (p<0.05 in most of the age 
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groups) and was the major contributor to the reduction of their mean SBP, accounting 
for -0.68 mmHg (95% CI: -1.21 to -0.16 mmHg) in 30–34 years, -0.93 mmHg (95% CI: 
-1.59 to -0.28 mmHg) in 40–44 years, and -1.09 mmHg (95% CI: -1.86 to -0.33 mmHg) 
in 45–49 years. The trend of mean BMI reversed in elderly women, with an associated 
increase in mean SBP of 1.48 mmHg (95% CI: 0.53–2.44 mmHg) in 65–69 years, 2.04 
mmHg (95% CI: 1.08–3.00 mmHg) in 70–74 years, and 1.09 mmHg (95% CI: 0.32–
1.85 mmHg) in those aged 75 years and over. Mean BMI significantly rose across all 
age groups in men (p<0.05 among those under 60 years and p<0.001 in 60 years and 
over), with an associated increase in mean SBP of up to 2.60 mmHg (95% CI: 1.82–
3.39 mmHg) in 70–74 years. 
The contributions of reduced mean daily salt intake were significant but only 
marginal at -0.4 to -0.2 mmHg across all age groups in both sexes. These values should 
be interpreted with caution, because as mentioned above, the measure of salt intake used 
in this study was an aggregate at the prefecture level. 
The contributions of alcohol consumption to mean SBP were mixed across sex 
and age groups, due to the different trends in the prevalence of drinking (Table 2.9). The 
decrease in the prevalence of alcohol consumption among men in their 30s was 
associated with a reduction of mean SBP by -0.31 mmHg (95% CI: -0.52 to -0.10 
mmHg) in those aged 30–34 years and by -0.22 mmHg (95% CI: -0.42 to -0.03 mmHg) 
in those aged 35–39 years. In contrast, the prevalence of alcohol drinking significantly 
rose in men aged 70 years and over (p<0.05), with an associated increase in mean SBP 
by 0.35 mmHg (95% CI: 0.10–0.60 mmHg) in 70–74 years and by 0.25 mmHg (95% 
CI: 0.02–0.48 mmHg) in 75 years and over. The prevalence of alcohol consumption 
also increased in women younger than 60 years with statistical significance (p<0.001 in 
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most of the age groups), and a concomitant rise in their mean SBP by 0.2 mmHg was 
noted. 
Regular exercise contributed very little to the decline of mean SBP by less than 
0.1 mmHg in all age groups in both sexes. This minor effect of physical activity was 
largely attributable to its small association with individual SBP, given that the 
prevalence of regular exercise increased substantially across all sex and age groups 
during the period (Table 2.9). 
Finally, after considering both positive and negative contributions to the decline 
of mean SBP, a remaining reduction of 2.44 mmHg in men and 3.14 mmHg in women 
was left unexplained by this model. These values were constant across age groups and 
equivalent to the coefficients of the survey year 2002 estimated in the second-stage 
regression. 
 
2.4 Discussion 
 
This chapter presented the first attempt to measure the contributions of the 
trends in lifestyle-related factors and antihypertensive treatment to the decline of mean 
SBP in Japan. The original feature of this study was the application of an econometric 
approach to the analysis of the pooled dataset of the national cross-sectional surveys 
conducted over a long period of time, in order to obtain unbiased estimates on the 
association of antihypertensive medications with SBP. 
The study identified two major contributors to the change of mean SBP in Japan 
during the 17-years study period. First, the effect of antihypertensive medications was 
substantial in older adults. It was a product of the association between SBP and 
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antihypertensive medications and the change in the probability of taking medications. 
The considerable association of treatment with SBP that was observed by using this 
instrumental variable approach raises questions concerning whether this might have 
been an overestimation or patients that receive treatment in Japan have been managed 
exceptionally well. Although the NNS did not ask which antihypertensive drug class the 
study participants used, the most frequently prescribed drugs were thiazide diuretics and 
beta-blockers during the 1980s (Ebihara 1997; Ishii 1999), while calcium channel 
blockers and angiotensin-converting enzyme inhibitors were the most popular since the 
1990s (Mori et al. 2006; Muratani et al. 1996; Saruta 1998). Previous meta-analyses 
assessed the average effects of antihypertensive medications on SBP to be 9–15 mmHg 
for single-drug standard-dose therapies and 20 mmHg for three-drug regimens in people 
having a cardiovascular event and usual pretreatment blood pressure at 150/90 mmHg 
(Law, Wald, Morris and Jordan 2003; Wu et al. 2005). Our estimates therefore 
approximated treatment effects well for this type of analysis based on cross-sectional 
survey data. Moreover, the considerable increase in the probability of being treated in 
older adults might be partly attributable to the improved awareness of physicians about 
the importance of diagnosis and treatment of hypertension through the publication of 
several journal articles or guidelines for the management of hypertension in Japan 
during this period (Hiwada et al. 1999; Japanese Society of Hypertension 2001; 
Ministry of Health and Japan Medical Association 1990; Ogihara et al. 1996). This 
issue is addressed in greater detail in the next chapter. In addition, this study suggested 
that there might be still considerable room for a further decrease in mean SBP through 
enhanced treatment coverage and control of hypertension. This was especially the case 
for men, who had poorer coverage and control rates than women in 2002. 
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Another principal finding of this study was that the contribution of decreased 
mean BMI was substantial in women in their 30s and 40s, whereas increased mean BMI 
offset a large part of the decrease of mean SBP in men and elderly women. These 
different trends of BMI across sex and age groups in Japan were reported elsewhere 
(Yoshiike et al. 2002). Although the decreasing trend of mean BMI brought favorable 
consequences in young women, it must be noted that the trend of excessive thinness can 
ultimately result in adverse health outcomes (Takimoto, Yoshiike, Kaneda and Yoshita 
2004). 
The present study is the first to confirm in the Japanese context the adverse 
effect of overweight and obesity on population blood pressure which had been 
suggested in previous studies (Burt et al. 1995; Hajjar and Kotchen 2003; Tunstall-
Pedoe et al. 2006). A major physiological mechanism that lead to hypertension during 
the development of obesity is increased renal sodium reabsorption and impaired 
pressure natriuresis, mediated by increased sympathetic nervous system activity, 
activation of the renin-angiotensin-aldosterone system, and physical compression of 
kidneys (Hall 2003). Obese individuals require increased arterial pressure to maintain a 
balance between intake and renal excretion of sodium. Formulating effective policies to 
control the obesity epidemic would be extremely urgent to prevent obesity-induced 
hypertension and the future disease burden from CVD, particularly in Japanese men. 
Lifestyle-related factors such as physical activity, alcohol drinking, and dietary 
salt intake made only limited contributions to the decline of mean SBP in this study. 
Nevertheless, improving lifestyle will undoubtedly have a beneficial effect on reducing 
mean SBP at the population level. The negligible contribution of regular exercise was 
largely attributable to its small association with SBP at the individual level, which was 
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unexpected. However, it might be ascribed to potential confounding factors between 
physical activity and SBP that were not included in our model (Fagard 1999), or to the 
possibility that there might be multiple physiological paths for its protective effects 
(United States Department of Health and Human Services 1996). Further investigation 
on the association between physical activity and blood pressure will be necessary in 
future research. Moreover, the contribution of alcohol drinking was very small because 
its prevalence did not change much during this period. Given that alcohol consumption 
showed a relatively large association with SBP, an adequate decrease in the prevalence 
of alcohol consumption would bring a considerable decline in mean SBP, especially in 
Japanese men. Furthermore, this study demonstrated that cigarette smoking had a 
negligible association with SBP, which was consistent with a previous finding from 
England that made use of survey data (Primatesta, Falaschetti, Gupta, Marmot and 
Poulter 2001). This might sound counterintuitive because it is well known that smoking 
cessation is important for total cardiovascular risk reduction. Smoking, however, raises 
blood pressure only acutely, and blood pressure returns to its baseline level a quarter of 
an hour after smoking ceases (Chobanian et al. 2003). SBP measured during these 
surveys, therefore, does not reflect the effects of cigarette smoking, and it can be safely 
said that the finding from this study is valid. 
These findings and their implications are relevant to health policies in countries 
where the prevalence of hypertension or mean SBP is expected to rise (Hajjar and 
Kotchen 2003; Kearney et al. 2005). Continued efforts should be made to encourage the 
maintenance of adequate body weight, to keep alcohol consumption and salt intake to a 
minimum, and to improve the management of hypertension. The introduction of 
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affordable medications such as multidrug regimens would be particularly helpful in 
developing countries (Gaziano, Opie and Weinstein 2006). 
 Several limitations of this study should be taken into consideration in the 
interpretation of its findings. First, even with the use of an instrumental variable a 
causal relationship cannot be derived from these cross-sectional data. Use of 
longitudinal data that follow a nationally representative sample would be one of 
strategies to strengthen the assessment of the impact of relevant factors on blood 
pressure. 
 Second, as with all data from interview and examination surveys, the data used 
in this study might contain measurement errors resulting from a white-coat effect on the 
first measurement of clinic blood pressure, changes in questioning techniques over the 
study period of 17 years, and self-reports of antihypertensive medications and lifestyles. 
Especially with regard to the blood pressure measurement, it might be worth 
considering in future surveys to introduce 24-hour ambulatory blood pressure 
monitoring or home blood pressure measurements. These measurements in a non-
clinical setting would not only reduce the bias but complement casual blood pressures 
with important information on morning hypertension and nighttime blood pressure to 
improve our understanding of cardiovascular risk profiles of the population. 
 Third, due to the nature of the treatment variable, this study assumed that the 
treatment effect was constant between 1986 and 2002, ignoring the technological 
advance in antihypertensive drugs. Given that there has been a change in the pattern of 
use of antihypertensive agents during the study period as described above, incorporating 
questions in the survey to ask which drug they are taking would ensure more accurate 
understanding of the treatment effects on population blood pressure in the long term.  
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 Finally, the present study left a substantial part of the reduction in mean SBP to 
be unexplained, which may be partly attributable to the limited availability of 
explanatory variables from the survey. For example, apart from the dietary salt, the 
model presented in this study did not include the intake of key nutrients, such as 
calcium, magnesium, potassium, and vegetable protein, in order to minimize estimation 
bias resulting from the aggregation of data, as described above. Other potentially 
relevant variables of interest that were not available included educational background, 
marital status, occupation, income, urban/rural dwelling, psychosocial factors (e.g. 
family responsibilities and job strain), the quantity of alcohol consumption, the quantity 
and intensity of physical activity, and birth weight. Data on these and other variables 
should be extensively collected and incorporated in the model in future research. 
Further development and refinement of the statistical methods for addressing treatment 
effects may also improve our capacity to explain the decrease in average blood 
pressures in some general populations. 
In conclusion, the decline of mean SBP in Japan between 1986 and 2002 was 
partly attributable to the increased likelihood of taking antihypertensive medications, 
especially among older adults, and decreased mean BMI among young and middle-aged 
women. In order to achieve a further decrease in the population average SBP of 
Japanese adults, policies should be strengthened with particular attention to the 
management of body weight among men and elderly women, the reduction of dietary 
salt intake and alcohol consumption, and the improvement in the treatment coverage 
and control of hypertension. 
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Table 2.1 Description of variables used in the regression analysis, based on data from the National Nutrition Survey, Japan, 
1986–2002 
 
Variable Survey year Possible values Reference categories/  
analytic strategies 
Measured systolic blood pressure 1986–2002 Continuous in mmHg  
Age (years) 1986–2002 20–29, 30–34, 35–39, 40–44, 45–49, 50–
54, 55–59, 60–64, 65–69, 70–74, 75+ 
“20–29” 
Measured body mass index 1986–2002 Continuous in kg/m2 Interacted with age 
Regular exercise 1986–1989 “Yes”/“No” “No” 
 1990–2002 “Unable to do for health reasons,” 
“Unable to do for other reasons,” 
“Currently doing regular exercise” 
“Unable to do for health reasons” 
or “Unable to do for other 
reasons” 
Current smoker 1986–2002 “Never,” “Discontinued,” “Currently 
smoking” 
“Never” or “Discontinued” 
Current drinker 1986–1989 “Yes”/“No” “No” 
 1990–2002 “Never or rarely,” “Discontinued,” 
“Currently drinking” 
“Never or rarely” or 
“Discontinued” 
Daily salt intake per capita by prefecture 1986–2002 Salt intake in grams  
Antihypertensive medication use 1986–1989 “Taking,” “Not taking” “Not taking” 
 1990–2002 “Never,” “Discontinued,” “Taking 
occasionally,” “Taking daily” 
“Never,” “Discontinued” or 
“Taking occasionally” 
Survey year 1986–2002 1986–2002 1986 
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Table 2.2 Age-standardized means of key variables in the adult population over 20 years of age, by sex, based on imputed data 
from the National Nutrition Survey, Japan, in 1986 and 2002 
 
Variables Men     Women    
 1986 (n = 6,612) 2002 (n = 4,278) p-valuese 1986 (n = 7,224) 2002 (n = 4,897) p-valuese
 Mean 95% CI Mean 95% CI  Mean 95% CI Mean 95% CI 
Body mass index kg/m2 22.5 22.5–22.6 23.3 23.2–23.4 <0.001 22.4 22.4–22.5 22.4 22.3–22.5 0.652
Regular exercise % 21.5 20.5–22.6 32.2 30.8–33.6 <0.001 14.9 14.0–15.7 29.0 27.7–30.3 <0.001
Current smoker % 55.1 53.9–56.4 43.9 42.4–45.4 <0.001 9.3 8.6–10.0 12.7 11.7–13.7 <0.001
Current drinker % 49.2 48.0–50.5 48.7 47.2–50.2 0.718 7.0 6.4–7.6 12.6 11.6–13.6 <0.001
Daily salt intake grams 12.1 12.1–12.2 11.8 11.7–11.8 <0.001 12.1 12.1–12. 1 11.7 11.7–11.8 <0.001
Prevalence of hypertension %a 43.7 42.5–44.8 42.9 41.6–44.2 0.529 38.3 37.4–39.3 35.3 34.1–36.4 0.004
Hypertensives on treatment %a,b,c 29.8 27.8–31.8 39.7 36.9–42.6 <0.001 36.3 33.5–39.2 48.0 44.3–51.7 0.002
Hypertensives on control %a,b,d 12.4 10.9–14.0 20.5 17.9–23.1 <0.001 17.5 14.8–20.1 27.2 23.7–30.8 <0.001
CI, confidence interval. 
a Hypertension was defined as a systolic blood pressure ≥140 mmHg or daily use of antihypertensive medication. 
b Out of hypertensive population. 
c Treatment was defined as daily use of antihypertensive medications. 
d Control was defined as a systolic blood pressure < 140 mmHg. 
e P-values for testing the null hypothesis of no difference in means between 1986 and 2002. 
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Table 2.3 Age-standardized mean systolic blood pressure (in mmHg), by sex and 
use or non-use of antihypertensive medications, based on imputed data from the 
National Nutrition Survey, Japan, 1986–2002 
 
Sex Untreated   Treated   p-valuea
 n Mean 95%CI n Mean 95%CI  
Men 76,781 133.5 133.3–133.6 13,773 140.4 140.0–140.8 <0.001
Women 85,728 128.7 128.6–128.8 16,175 138.4 138.0–138.8 <0.001
CI, confidence interval. 
a P-values for testing the null hypothesis of no difference in means between the untreated and treated 
groups. 
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Table 2.4 Age-standardized mean systolic blood pressure (in mmHg) in the adult population over 20 years of age, by sex and 
quintiles of antihypertensive treatment coverage at the prefecture level, based on imputed data from the National Nutrition 
Survey, Japan, 1986–2002 
 
Quintiles Mena    Womenb    
 n Mean 95% CI p-valuec n Mean 95% CI p-valuec 
1st 19,478 135.0 134.8–135.3 0.304 22,434 130.7 130.5–130.9 0.391 
2nd 19,719 134.6 134.4–134.9  19,143 130.1 129.8–130.3  
3rd 18,782 134.5 134.3–134.8  20,945 130.0 129.8–130.3  
4th 17,282 134.6 134.3–134.9  20,442 129.9 129.6–130.1  
5th 15,293 134.8 134.5–135.0  18,939 130.5 130.2–130.7  
CI, confidence interval. 
a The quintiles were, from first to fifth, 28.7–32.7%, 32.9–34.7%, 35.1–37.1%, 37.3–38.4% and 38.6–42.0%, respectively. 
b The quintiles were, from first to fifth, 33.1–38.9%, 39.3–40.7%, 41.0–42.5%, 42.9–44.5% and 44.8–52.7%, respectively. 
c P-values for testing the null hypothesis of no difference in means between the first and fifth quintiles. 
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Table 2.5 Proportions of hypertensive patients who were on antihypertensive 
medication, by sex and prefecture, based on imputed data from the National 
Nutrition Survey, Japan, 1986–2002 
 
Prefecture Male   Female   
 n Mean 95% CI n Mean 95% CI 
Hokkaido 1,616 0.395 0.371–0.419 1,691 0.434 0.411–0.458 
Aomori 429 0.401 0.356–0.448 478 0.483 0.439–0.528 
Iwate 411 0.394 0.348–0.442 468 0.487 0.442–0.532 
Miyagi 680 0.400 0.364–0.437 672 0.500 0.462–0.538 
Akita 445 0.411 0.366–0.458 468 0.521 0.476–0.566 
Yamagata 515 0.388 0.347–0.431 509 0.517 0.473–0.560 
Fukushima 836 0.374 0.342–0.408 824 0.460 0.426–0.494 
Ibaraki 1,029 0.384 0.355–0.414 1,009 0.477 0.446–0.508 
Tochigi 661 0.333 0.298–0.370 643 0.437 0.399–0.476 
Gumma 714 0.339 0.305–0.374 669 0.422 0.385–0.459 
Saitama 2,051 0.374 0.353–0.395 1,868 0.416 0.394–0.439 
Chiba 1,473 0.369 0.344–0.394 1,390 0.441 0.415–0.467 
Tokyo 2,916 0.379 0.361–0.396 2,734 0.439 0.420–0.458 
Kanagawa 2,392 0.385 0.366–0.405 2,096 0.419 0.398–0.440 
Niigata 1,130 0.379 0.351–0.407 1,103 0.461 0.431–0.490 
Toyama 337 0.323 0.276–0.375 326 0.393 0.341–0.447 
Ishikawa 421 0.328 0.285–0.374 437 0.446 0.400–0.493 
Fukui 329 0.313 0.265–0.365 340 0.418 0.366–0.471 
Yamanashi 358 0.330 0.283–0.380 356 0.365 0.317–0.416 
Nagano 738 0.392 0.357–0.427 760 0.458 0.423–0.493 
Gifu 708 0.355 0.320–0.390 766 0.406 0.372–0.441 
Shizuoka 1,103 0.362 0.334–0.391 1,118 0.394 0.366–0.423 
Aichi 2,037 0.356 0.335–0.377 1,905 0.401 0.379–0.423 
Mie 602 0.307 0.272–0.345 635 0.397 0.359–0.435 
Shiga 407 0.344 0.299–0.391 384 0.393 0.346–0.443 
Kyoto 854 0.344 0.313–0.377 821 0.386 0.353–0.420 
Osaka 2,334 0.344 0.325–0.364 2,319 0.397 0.377–0.417 
Hyogo 1,687 0.329 0.307–0.352 1,714 0.379 0.357–0.402 
Nara 328 0.363 0.313–0.416 316 0.437 0.383–0.492 
Wakayama 384 0.299 0.256–0.347 444 0.378 0.334–0.424 
Tottori 214 0.369 0.307–0.436 209 0.416 0.351–0.484 
Shimane 325 0.348 0.298–0.401 344 0.427 0.376–0.480 
Okayama 682 0.342 0.307–0.378 728 0.409 0.374–0.445 
Hiroshima 904 0.332 0.302–0.363 890 0.412 0.380–0.445 
Yamaguchi 604 0.316 0.280–0.354 686 0.362 0.326–0.398 
CI, confidence interval. 
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Table 2.5 (Continued) 
 
Prefecture Male   Female   
 n Mean 95% CI n Mean 95% CI 
Tokushima 292 0.380 0.326–0.437 294 0.381 0.327–0.438 
Kagawa 397 0.312 0.269–0.360 423 0.331 0.288–0.377 
Ehime 498 0.299 0.261–0.341 509 0.352 0.311–0.394 
Kochi 273 0.341 0.287–0.399 315 0.425 0.372–0.481 
Fukuoka 1,487 0.324 0.301–0.348 1,606 0.368 0.345–0.392 
Saga 310 0.339 0.288–0.393 313 0.374 0.322–0.429 
Nagasaki 435 0.347 0.304–0.393 493 0.446 0.403–0.490 
Kumamoto 660 0.289 0.256–0.325 651 0.379 0.343–0.417 
Oita 454 0.317 0.276–0.361 537 0.441 0.400–0.484 
Miyazaki 383 0.363 0.316–0.412 407 0.418 0.371–0.466 
Kagoshima 675 0.311 0.277–0.347 682 0.419 0.383–0.457 
Okinawa 302 0.305 0.255–0.359 296 0.439 0.384–0.496 
CI, confidence interval. 
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Table 2.6 Results from the first-stage logistic regression model on current use of 
antihypertensive medication, based on imputed data from the National Nutrition 
Survey, Japan, 1986–2002 
 
Independent  Men (n = 90,554)  Women (n = 101,903)  
variables OR 95% CI p-value OR 95% CI p-value
BMI (kg/m2) 1.03 1.00–1.06 0.046 1.08 1.04–1.12 0.002
Age (years)a    
30–34 1.15 0.35–3.75 0.824 1.75 0.48–6.32 0.403
35–39 0.93 0.31–2.74 0.893 1.14 0.33–3.89 0.840
40–44 0.96 0.31–2.95 0.948 1.39 0.53–3.61 0.504
45–49 1.14 0.43–3.02 0.804 1.04 0.47–2.32 0.914
50–54 0.88 0.34–2.23 0.787 1.36 0.54–3.43 0.519
55–59 1.05 0.46–2.42 0.908 1.51 0.64–3.57 0.356
60–64 1.20 0.51–2.83 0.681 3.16 1.35–7.37 0.014
65–69 1.38 0.62–3.05 0.437 4.22 1.74–10.22 0.005
70–74 2.75 1.09–6.90 0.043 6.62 2.96–14.90 <0.001
≥ 75 3.56 1.39–9.09 0.017 14.01 6.08–32.34 <0.001
Age (years) × BMI    
30–34 × BMI 1.00 0.95–1.05 0.994 0.96 0.91–1.03 0.264
35–39 × BMI 1.01 0.97–1.06 0.562 0.99 0.93–1.05 0.697
40–44 × BMI 1.02 0.98–1.07 0.360 1.00 0.95–1.04 0.933
45–49 × BMI 1.03 0.99–1.08 0.180 1.03 0.99–1.07 0.161
50–54 × BMI 1.05 1.01–1.10 0.018 1.03 0.99–1.08 0.139
55–59 × BMI 1.06 1.02–1.10 0.003 1.05 1.01–1.09 0.035
60–64 × BMI 1.06 1.03–1.11 0.002 1.03 0.99–1.07 0.169
65–69 × BMI 1.07 1.04–1.11 <0.001 1.03 0.99–1.08 0.144
70–74 × BMI 1.05 1.01–1.10 0.014 1.03 0.99–1.07 0.128
≥ 75 × BMI 1.05 1.01–1.10 0.024 1.01 0.97–1.05 0.691
Regular exercisea 1.09 1.02–1.17 0.034 1.06 1.01–1.12 0.034
Current smokera 0.75 0.72–0.78 <0.001 1.00 0.91–1.10 0.940
Current drinkera 1.09 1.04–1.14 <0.001 1.14 1.03–1.27 0.025
Daily salt intake (g) 1.02 0.99–1.04 0.180 1.03 1.00–1.05 0.023
Antihypertensive  
treatment coverage  
by prefecture 
47.47 22.54–100.82 <0.001 16.12 8.85–29.18 <0.001
BMI, body mass index; OR, odds ratio; CI, confidence interval. 
a Reference categories: 20–29 years old, no regular exercise, non/ex-smoker, non/ex-drinker, year 1986. 
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Table 2.6 (Continued) 
 
Independent  Men (n = 90,554)  Women (n = 101,903)  
variables OR 95% CI p-value OR 95% CI p-value
Survey yeara   
1987 1.13 1.01–1.26 0.027 1.07 0.96–1.20 0.228
1988 1.04 0.93–1.18 0.481 1.06 0.94–1.19 0.330
1989 1.08 0.96–1.22 0.193 1.04 0.93–1.17 0.473
1990 1.03 0.90–1.19 0.643 1.07 0.95–1.21 0.246
1991 1.00 0.89–1.13 0.965 0.93 0.83–1.05 0.277
1992 1.03 0.90–1.17 0.688 1.02 0.91–1.16 0.692
1993 1.07 0.95–1.21 0.266 1.09 0.97–1.23 0.132
1994 1.03 0.89–1.19 0.677 1.03 0.92–1.15 0.645
1995 1.07 0.94–1.23 0.317 1.12 0.99–1.26 0.067
1996 1.14 1.00–1.31 0.064 1.07 0.95–1.22 0.276
1997 1.11 0.95–1.29 0.193 1.07 0.94–1.21 0.300
1998 1.19 1.05–1.34 0.008 1.14 1.02–1.28 0.025
1999 1.21 1.07–1.38 0.005 1.17 1.04–1.32 0.010
2000 1.17 1.01–1.36 0.047 1.20 1.06–1.34 0.004
2001 1.22 1.07–1.41 0.007 1.20 1.07–1.34 0.002
2002 1.28 1.12–1.46 0.001 1.27 1.13–1.43 <0.001
LR chi2 8594.1 <0.001 15209.8  <0.001
Pseudo R-squared 0.11 0.17  
BMI, body mass index; OR, odds ratio; CI, confidence interval. 
a Reference categories: 20–29 years old, no regular exercise, non/ex-smoker, non/ex-drinker, year 1986. 
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Table 2.7 Results from the second-stage linear regression model on systolic blood 
pressure, based on imputed data from the National Nutrition Survey, Japan, 1986–
2002 
 
Independent variables Men (n = 90,554) Women (n = 101,903) 
 b SE p-value b SE p-value
BMI (kg/m2) 1.36 0.07 <0.001 1.29 0.05 <0.001
Age (years)a   
30–34 4.30 2.44 0.095 0.97 1.79 0.587
35–39 4.90 2.73 0.100 0.89 1.87 0.637
40–44 8.84 2.85 0.011 3.04 1.73 0.081
45–49 9.84 2.28 <0.001 2.35 1.69 0.165
50–54 12.21 2.13 <0.001 5.23 1.97 0.010
55–59 14.76 2.47 <0.001 6.19 2.68 0.038
60–64 19.45 2.35 <0.001 13.89 2.18 <0.001
65–69 20.65 2.69 <0.001 19.36 2.70 <0.001
70–74 28.10 2.60 <0.001 28.71 1.99 <0.001
≥ 75 30.99 2.24 <0.001 39.67 1.79 <0.001
Age (years) × BMI   
30–34 × BMI -0.05 0.11 0.626 0.07 0.08 0.428
35–39 × BMI 0.02 0.12 0.903 0.22 0.09 0.016
40–44 × BMI -0.02 0.13 0.891 0.33 0.08 <0.001
45–49 × BMI 0.10 0.10 0.333 0.58 0.08 <0.001
50–54 × BMI 0.17 0.10 0.112 0.71 0.10 <0.001
55–59 × BMI 0.26 0.12 0.037 0.89 0.14 <0.001
60–64 × BMI 0.24 0.12 0.048 0.75 0.12 <0.001
65–69 × BMI 0.38 0.13 0.008 0.76 0.15 <0.001
70–74 × BMI 0.19 0.13 0.150 0.60 0.12 <0.001
≥ 75 × BMI 0.24 0.12 0.053 0.38 0.12 0.003
Regular exercisea -0.56 0.18 0.007 -0.35 0.19 0.085
Current smokera 0.39 0.19 0.048 0.38 0.27 0.186
Current drinkera 3.17 0.13 <0.001 2.41 0.23 <0.001
Daily salt intake (grams) 0.43 0.08 <0.001 0.44 0.07 <0.001
Predicted probability  
of treatment 
-20.50 3.16 <0.001 -32.52 4.56 <0.001
b, regression coefficient; BMI, body mass index; SE, standard error. 
a Reference categories: 20–29 years old, no regular exercise, non/ex-smoker, non/ex-drinker, year 1986. 
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Table 2.7 (Continued) 
 
Independent variables Men (n = 90,554) Women (n = 101,903) 
 b SE p-value b SE p-value
Survey yeara       
1987 0.33 0.34 0.335 -0.15 0.36 0.672
1988 0.08 0.33 0.821 0.06 0.35 0.861
1989 -0.51 0.36 0.166 -1.36 0.34 <0.001
1990 -0.88 0.32 0.007 -1.19 0.37 0.003
1991 -0.72 0.34 0.038 -1.30 0.43 0.008
1992 -0.87 0.37 0.022 -1.36 0.33 <0.001
1993 -1.60 0.43 0.001 -1.92 0.37 <0.001
1994 -2.10 0.45 <0.001 -2.45 0.37 <0.001
1995 -1.34 0.43 0.004 -2.29 0.38 <0.001
1996 -1.54 0.34 <0.001 -2.14 0.34 <0.001
1997 -1.68 0.45 0.002 -2.99 0.41 <0.001
1998 -2.33 0.40 <0.001 -3.07 0.32 <0.001
1999 -2.47 0.40 <0.001 -2.88 0.45 <0.001
2000 -2.90 0.47 <0.001 -3.69 0.40 <0.001
2001 -2.60 0.47 <0.001 -3.44 0.36 <0.001
2002 -2.44 0.56 0.001 -3.14 0.38 <0.001
Intercept 86.08 2.14 <0.001 83.29 1.35 <0.001
F 776.6 <0.001 1428.5  <0.001
Adjusted R-squared 0.26 0.37  
b, regression coefficient; BMI, body mass index; SE, standard error. 
a Reference categories: 20–29 years old, no regular exercise, non/ex-smoker, non/ex-drinker, year 1986. 
 
  37
Table 2.8 Change in age-specific means of systolic blood pressure (in mmHg) 
predicted from the two-stage regression model, by sex, between 1986 and 2002, 
based on imputed data from the National Nutrition Survey, Japan, 1986–2002 
 
Sex and age (years) Number surveyed Mean prediction Difference between means  
 1986 2002 1986 2002 Mean 95% CI  
Men        
20–29 993 540 121.6 119.1 -2.5 -2.9, -2.0 *
30–34 642 327 125.8 123.2 -2.6 -3.2, -2.0 *
35–39 1019 330 128.1 126.2 -1.9 -2.4, -1.4 *
40–44 702 321 131.5 128.9 -2.5 -3.0, -2.0 *
45–49 655 356 135.0 132.1 -2.8 -3.4, -2.3 *
50–54 667 476 138.0 135.3 -2.7 -3.2, -2.2 *
55–59 536 415 141.8 138.9 -2.9 -3.4, -2.3 *
60–64 482 418 144.5 141.8 -2.7 -3.2, -2.1 *
65–69 339 383 147.6 144.6 -3.0 -3.6, -2.4 *
70–74 261 324 148.1 146.3 -1.8 -2.5, -1.2 *
75+ 316 388 151.3 148.8 -2.5 -3.1, -1.8 *
Women        
20–29 980 570 114.4 110.7 -3.7 -4.1, -3.4 *
30–34 689 340 117.9 113.8 -4.1 -4.7, -3.6 *
35–39 989 326 121.7 117.6 -4.1 -4.7, -3.6 *
40–44 707 353 127.2 122.6 -4.6 -5.2, -4.0 *
45–49 731 387 131.6 126.7 -4.8 -5.5, -4.2 *
50–54 694 518 136.3 132.2 -4.2 -4.8, -3.6 *
55–59 659 478 140.1 135.0 -5.1 -5.7, -4.5 *
60–64 553 466 143.3 138.8 -4.6 -5.2, -3.9 *
65–69 433 419 146.1 142.0 -4.1 -4.7, -3.5 *
70–74 370 410 148.8 144.8 -4.0 -4.6, -3.5 *
75+ 419 630 152.6 147.9 -4.6 -5.1, -4.2 *
CI, confidence interval. 
* Difference between 1986 and 2002 is statistically significant with p<0.001. 
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Table 2.9 Change in age-specific means of explanatory variables by sex, between 1986 and 2002, based on imputed data from the 
National Nutrition Survey, Japan 
 
Sex and  
age (years) 
n  Pr(Med) BMI (kg/m2) Salt intake (grams) 
1986 2002 1986 2002 ∆ p-value 1986 2002 ∆ p-value 1986 2002 ∆ p-value 
Men               
20–29 993 540 4.2 5.7 1.5 0.256 21.9 22.5 0.5 0.003 12.1 11.4 -0.7 <0.001 
30–34 642 327 5.9 7.2 1.2 0.491 22.5 23.2 0.7 0.003 12.1 11.4 -0.7 <0.001 
35–39 1019 330 6.7 6.1 -0.6 0.329 22.7 23.8 1.1 <0.001 12.1 11.4 -0.6 <0.001 
40–44 702 321 8.1 8.6 0.5 0.501 23.0 23.7 0.6 0.009 12.0 11.4 -0.6 <0.001 
45–49 655 356 10.7 12.8 2.0 0.410 23.2 23.7 0.5 0.022 12.2 11.4 -0.8 <0.001 
50–54 667 476 12.8 19.5 6.7 0.003 23.1 23.7 0.6 0.003 12.1 11.4 -0.7 <0.001 
55–59 536 415 15.2 23.0 7.8 0.008 23.1 23.6 0.6 0.008 12.1 11.4 -0.7 <0.001 
60–64 482 418 16.8 23.4 6.6 0.017 22.5 23.6 1.0 <0.001 12.2 11.3 -0.9 <0.001 
65–69 339 383 29.9 33.9 4.0 0.258 22.6 23.6 1.0 <0.001 12.3 11.4 -0.9 <0.001 
70–74 261 324 27.4 39.3 11.9 0.006 21.8 23.5 1.7 <0.001 12.1 11.4 -0.7 <0.001 
≥75 316 388 32.4 44.3 11.9 0.011 21.7 22.9 1.2 <0.001 12.3 11.4 -0.9 <0.001 
Women               
20–29 980 570 3.1 5.1 2.0 0.180 20.8 20.7 -0.1 0.467 12.1 11.4 -0.7 <0.001 
30–34 689 340 2.8 5.1 2.3 0.087 21.5 21.0 -0.5 0.015 12.1 11.4 -0.7 <0.001 
35–39 989 326 3.7 3.9 0.1 0.553 22.1 21.7 -0.4 0.068 12.0 11.4 -0.6 <0.001 
40–44 707 353 5.2 7.3 2.1 0.180 22.9 22.4 -0.6 0.009 12.1 11.4 -0.8 <0.001 
45–49 731 387 7.3 9.1 1.9 0.374 23.2 22.6 -0.6 0.006 12.0 11.4 -0.7 <0.001 
50–54 694 518 12.7 15.1 2.5 0.236 23.2 23.2 0.0 0.772 12.1 11.3 -0.8 <0.001 
55–59 659 478 16.7 17.2 0.5 0.731 23.4 22.9 -0.4 0.034 12.2 11.4 -0.8 <0.001 
60–64 553 466 22.6 22.8 0.2 0.687 23.4 23.6 0.2 0.381 12.2 11.3 -0.9 <0.001 
65–69 433 419 30.2 35.9 5.8 0.084 23.0 23.7 0.7 0.005 12.1 11.4 -0.7 <0.001 
70–74 370 410 34.4 44.6 10.2 0.006 22.8 23.9 1.1 <0.001 12.3 11.4 -0.9 <0.001 
≥75 419 630 39.3 47.6 8.3 0.014 22.4 23.1 0.7 0.007 12.1 11.4 -0.8 <0.001 
BMI, body mass index; Pr(Med), probability of taking antihypertensive medication. 
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Table 2.9 (Continued) 
 
Sex Current drinker (%) Regular exercise (%) Current smoker (%) 
Age (years) 1986 2002 ∆ p-value 1986 2002 ∆ p-value 1986 2002 ∆ p-value
Men          
20–29 41.4 38.2 -3.2 0.336 22.9 27.7 4.8 0.070 61.8 48.3 -13.5 <0.001
30–34 53.3 43.5 -9.8 0.026 17.9 26.0 8.1 0.008 60.2 51.2 -9.1 0.020
35–39 56.4 49.4 -7.1 0.052 18.7 26.5 7.9 0.005 62.6 49.7 -13.0 <0.001
40–44 58.9 54.4 -4.5 0.288 18.0 28.5 10.5 0.002 56.4 52.1 -4.4 0.272
45–49 58.9 55.7 -3.2 0.466 18.0 28.7 10.7 <0.001 54.0 46.9 -7.0 0.094
50–54 54.0 57.2 3.2 0.324 17.5 33.0 15.6 <0.001 53.2 45.8 -7.3 0.062
55–59 52.2 56.0 3.8 0.296 18.2 31.6 13.4 <0.001 56.3 44.0 -12.3 <0.001
60–64 53.4 53.9 0.5 0.807 24.0 42.0 18.0 <0.001 53.4 41.1 -12.3 <0.001
65–69 45.6 46.8 1.2 0.720 26.8 40.0 13.2 <0.001 54.2 30.8 -23.4 <0.001
70–74 36.2 47.3 11.0 0.011 28.0 39.5 11.5 0.007 43.1 29.8 -13.4 0.001
≥75 35.6 43.6 7.9 0.041 28.5 39.8 11.3 0.003 41.0 32.3 -8.7 0.025
Women             
20–29 8.9 14.9 6.0 0.002 13.0 22.4 9.3 <0.001 12.1 17.0 4.9 0.020
30–34 7.1 15.6 8.5 <0.001 11.1 21.4 10.3 <0.001 12.2 17.3 5.1 0.036
35–39 7.4 11.2 3.9 0.033 13.0 22.9 10.0 <0.001 10.1 18.6 8.5 <0.001
40–44 8.1 16.3 8.2 <0.001 12.4 25.6 13.1 <0.001 9.5 16.3 6.8 0.002
45–49 6.8 14.5 7.7 <0.001 13.3 26.7 13.4 <0.001 7.6 13.2 5.6 0.005
50–54 7.3 15.2 8.0 <0.001 14.2 30.0 15.9 <0.001 8.2 12.4 4.2 0.024
55–59 5.0 13.1 8.1 <0.001 13.6 35.3 21.6 <0.001 8.1 7.9 -0.2 0.821
60–64 5.4 9.0 3.6 0.049 18.9 39.4 20.5 <0.001 8.0 8.7 0.7 0.738
65–69 5.6 7.4 1.8 0.339 21.3 37.9 16.7 <0.001 7.4 8.8 1.3 0.440
70–74 5.7 6.7 1.0 0.414 20.0 33.4 13.4 <0.001 9.9 6.2 -3.7 0.100
≥75 6.6 8.4 1.8 0.256 17.9 34.5 16.5 <0.001 6.3 6.0 -0.3 0.579
BMI, body mass index; Pr(Med), probability of taking antihypertensive medication. 
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Figure 2.1 Relationships of a valid instrumental variable with an endogenous 
treatment variable and an outcome variable in the two-stage regression model 
based on observational data. Dashed lines indicate that the instrumental variable 
should have no independent relationship with the outcome variable either directly 
or indirectly via other covariates. IV, instrumental variable. 
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Figure 2.2 Age-standardized mean and 95% confidence interval of systolic blood 
pressure in the adult population over 20 years of age, by sex, based on imputed 
data from the National Nutrition Survey, Japan, 1986–2002. Filled square, men; 
filled triangle, women. Error bars indicate 95% confidence intervals. 
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Figure 2.3 Estimated contributions of explanatory variables to changes in mean 
predicted systolic blood pressure in Japanese men (A) and women (B) between 
1986 and 2002, based on imputed data from the National Nutrition Survey, Japan, 
1986–2002. BMI, body mass index. 
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CHAPTER 3 
Awareness of the Japanese Society of Hypertension Guidelines for the 
Management of Hypertension (JSH 2000) and adherence to its 
recommendations: physician surveys in 2000 and 2004 
 
 
3.1 Background and objectives 
 
Hypertension is one of the risk factors of stroke and heart disease, which are the 
second and third leading causes of mortality in Japan. Despite the enormous burden of 
hypertension on society, the disease has not been effectively controlled yet in this 
country: the study in Chapter 2 revealed that, in 2002, only less than a third of 
hypertensive adults had their systolic blood pressures under control with 
antihypertensive medication. 
The mechanisms of the unsatisfactory control of blood pressure are complex and 
multifaceted. It might be partly attributable to the insufficient adherence of clinic 
physicians to evidence-based medicine and guideline recommendations, as well as to 
the inadequate compliance of patients with therapeutic instructions (Asch, Kerr, 
Lapuerta, Law and McGlynn 2001; Hagemeister et al. 2001; Milchak, Carter, James and 
Ardery 2004). In order to address the clinical aspects of the blood pressure control, a 
number of national and international societies have developed clinical guidelines for the 
management of hypertension to help physicians improve the early detection and 
effective treatment of raised blood pressure in their practice (Chobanian et al. 2003; 
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Cifkova et al. 2003; Hagemeister et al. 2001; McAlister, Teo, Lewanczuk, Wells and 
Montague 1997; Williams et al. 2004; World Health Organization 2003). Although 
definitions vary across studies and there is room for refinement in the accuracy of the 
measurement of adherence (Milchak et al. 2004), a number of studies have assessed 
physicians’ awareness of and adherence to these hypertension guidelines, concluding 
that they failed to achieve sufficient adherence in clinical practice (Asch et al. 2001; 
Cuspidi et al. 2002; Dickerson, Garratt and Brown 1995). For instance, an internet 
questionnaire survey of general practitioners conducted in the United Kingdom in 2006 
revealed their inadequate adherence to the recommendations of the British hypertension 
guidelines, particularly to those concerning home/self-monitoring, statin therapy, and 
the initial measurement of blood pressures in both arms (Heneghan, Perera, Mant and 
Glasziou 2007). 
In Japan, the Japanese Society of Hypertension announced the Guidelines for the 
Management of Hypertension in June 2000 (JSH 2000) (Japanese Society of 
Hypertension 2001). JSH 2000 was the first official clinical guidelines on the 
management of hypertension in this country since a handbook had been published in 
1990 by the Ministry of Health and the Japan Medical Association (Ministry of Health 
and Japan Medical Association 1990). The classification of blood pressures by JSH 
2000 followed the recommendations of the Sixth Report of the Joint National 
Committee on Prevention, Detection, Evaluation, and Treatment of High Blood 
Pressure (JNC VI) and the 1999 World Health Organization/International Society of 
Hypertension Guidelines (WHO/ISH): “optimal” at <120/80 mmHg, “normal” at 
<130/85 mmHg, “normal high” at 130–139/85–89 mmHg, “mild” at 140–159/90–99 
mmHg, “moderate” at 160–179/100–109 mmHg, and “severe” at ≥180/110 mmHg. 
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Moreover, considering the progression of cerebral arteriosclerosis and the decline in 
cerebral circulation with age, JSH 2000 specified higher thresholds of blood pressure 
for starting antihypertensive therapies on the elderly patients: 140–160/90 mmHg for 
those in their 60s; 160–170/90 mmHg for those in their 70s; and 160–180/90 mmHg for 
those in their 80s. Furthermore, JSH 2000 undertook a risk stratification of the JNC VI 
to categorize hypertension into low, moderate, and high risks. The guidelines 
recommended that patients with low- and moderate-risk hypertension should be 
prescribed with lifestyle modification for the first six and three months, respectively, 
and then switch to pharmacological treatment if blood pressure is still not controlled 
under 140/90 mmHg. The guidelines also suggested that lifestyle modification and 
pharmacological treatment should be simultaneously used for patients having high-risk 
hypertension. 
A couple of previous studies have evaluated the current status of the 
management of hypertension in Japan with reference to JSH 2000. One was a cross-
sectional survey conducted on doctors who attended continuing medical education 
meetings in 2001 (Saito, Kawabe, Tsujioka, Hirose and Shibata 2002). This past study 
suggested that, while their attitudes toward the treatment of hypertension were still 
conservative in comparison to the recommendations of JSH 2000, they were in 
transition to more aggressive control of blood pressure. The other was a cross-sectional 
survey implemented on members of the Japan Physicians Association in the winter 
2002–2003 (Goto et al. 2003). They pointed out that clinic physicians attached 
importance to the conditions of individual patients in selecting blood-pressure lowering 
drugs based on the guidelines. Implications from these past studies, however, cannot be 
generalized to the context of the whole population of clinic physicians in the country, 
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because they were based on a sample of those who were assumed to be relatively 
committed to the management of high blood pressure. Moreover, no study has explored 
how the attitudes of clinic physicians toward the guideline recommendations have 
improved since its publication. The assessment of the guideline’s achievements in the 
education of clinic physicians would provide useful information to understand what 
might be the deficits and discuss how they should be handled in the revised editions of 
the JSH guidelines, in order to further improve the quality of care for hypertension. 
The objective of the present study was to examine whether JSH 2000 had gained 
acceptance across the entire population of clinic physicians in four years since its 
publication. Characteristics of those who did not agree with the new threshold of high 
blood pressure were also investigated to identify potential areas that should be 
addressed in strategies for further enhancement in the management of hypertension. 
 
3.2 Methods 
 
Subjects and study design 
Data were obtained from two postal questionnaire surveys of a nationally 
representative sample of clinic physicians. One of these was a survey on the 
management of hypertension, which was undertaken by the National Institute of Health 
Services and Management and the Japanese Society of Hypertension in March 2000 
prior to the announcement of JSH 2000. The objective of this survey was to understand 
the routine clinical practice in the management of hypertension and explore the role of 
the guideline. A questionnaire was posted to 4,800 clinic offices, which were selected 
by simple random sampling from a total of 60,211 clinic offices nationwide that 
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registered general internal medicine as one of their specialties under the Medical Care 
Law (the sampling rate: 8%). One clinic physician working at each of these sampled 
clinic offices filled in the questionnaire and returned it by post. The questionnaire 
included twelve items which elicited the information relating to: 1) the basic 
characteristics of physicians such as their age, department, and daily patient load; 2) the 
treatment of hypertension; 3) recognition of the scheduled announcement of JSH 2000 
and their attitude toward the guidelines; and 4) self-monitoring of patients by using a 
device for home blood pressure measurement (Appendix 1). 
The other source of data was a survey on the awareness of clinical guidelines for 
the management of eight diseases, which were hypertension, diabetes, asthma, prostate 
hypertrophy, allergic rhinitis, and hypercholesterolemia. This survey aimed to assess the 
current status of awareness and implementation of these guidelines in clinical practice. 
In April 2004, a questionnaire was mailed to 10,000 clinic offices that were selected by 
simple random sampling from 61,917 clinic offices which were of the same kind that 
had participated in the 2000 survey (the sampling rate: 16%). The questionnaire was 
filled in and collected in the same way as in the 2000 survey. The 2004 survey 
questionnaire consisted of four sections: 1) respondents’ awareness, access, 
understanding, and use of each guideline; 2) their compliance to the recommendations 
of each guideline; 3) general questions about the usefulness and development of clinical 
guidelines; and 4) basic characteristics of respondents including their age, working 
department, and the composition of diseases in their outpatient care (Appendix 2). 
Both surveys were conducted as a part of research projects funded with Grants-
in-Aid for Scientific Research from MHLW (the former Ministry of Health until 2000). 
The survey in 2000 was conducted as a part of the Research on Disease Management of 
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Hypertension and Relevant Diseases (H12-iryo-002, the principal investigator: 
Toshihiko Hasegawa). I obtained the secondary data of this survey for the analysis with 
permission of the principal investigator. The survey in 2004 was implemented as a part 
of the Research on Evaluation of Clinical Guidelines (H14-iryo-035, the principal 
investigator: Tomonori Hasegawa). In this instance I participated in the whole process 
of the survey, including the survey design, development of the questionnaire, survey 
implementation, and the analysis of the primary data. 
 
Analysis 
Awareness of JSH 2000 
Awareness was measured with four indicators, that is, recognition, access, 
familiarity, and utilization. Recognition was defined as the state of having heard of the 
(scheduled) publication of JSH 2000. Access was defined as the state of having read the 
guideline. Familiarity was defined as the state of understanding the contents of the 
guideline. Utilization was defined as the state of having applied the guideline 
recommendations in clinical practice. 
The 2000 survey could only provide information on recognition, because it was 
conducted prior to the announcement of the guideline. In this survey, respondents chose 
one of four options, that is, “I have heard that JSH 2000 will soon be published and I 
would like to apply it in clinical practice,” “I have heard that JSH 2000 will soon be 
published, but I am not sure yet whether to apply it in clinical practice,” “I did not know 
that JSH 2000 will soon be published, but I would like to read its contents and examine 
whether to introduce it into clinical practice,” and “I did not know that JSH 2000 will 
soon be published, and I am not interested in it.” 
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In 2004, respondents answered “yes” or “no” to a question on recognition, 
“Have you ever heard of JSH 2000?” Those who answered affirmatively to this question 
further answered “yes” or “no” to a question on access, “Have you ever read the 
contents of the guideline?” Those who responded positively to this question then 
answered “yes” or “no” to a question on familiarity, “Have you understood the 
contents?” If they answered “yes” to this question, they further answered “yes” or “no” 
to a question on utilization, “Have you ever applied the recommendations of the 
guideline?” 
 
Adherence to JSH 2000 
The adherence of clinic physicians to JSH 2000 was assessed in relation to the 
recommendations on the management of low-risk hypertension and the threshold of 
blood pressure. Regarding the management of low-risk hypertension (i.e., 140–159/90–
99 mmHg without any cerebrovascular or cardiovascular risk factor other than 
hypertension), the 2000 survey asked respondents to select one treatment strategy which 
they thought was the most appropriate for each of the 140–149/90–94 mmHg and 150–
159/95–99 mmHg categories, using five options: “prescribing medicines,” “lifestyle 
modification at a medical facility,” “lifestyle modification at a non-medical facility such 
as health centers and municipalities,” “others,” and “no treatment.” The 2004 survey 
asked participants to choose all that applied in their management strategies of mild 
hypertension (140–159/90–99 mmHg) from five alternatives: “conducting lifestyle 
modification on their own,” “employing dietitians or public health nurses to perform 
lifestyle modification,” “referral to other healthcare providers because they could not 
treat these patients,” “prescribing medicines,” and “doing nothing.” 
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With regard to the threshold of blood pressure, the 2000 survey asked clinic 
physicians to report the levels of systolic and diastolic blood pressures at which they 
would start pharmacological treatment for 50-year-old and 80-year-old patients who had 
no comorbidity. The survey in 2004 asked participants whether they thought the new 
classification was appropriate or they preferred the old definition of 160/95 mmHg. In 
order to ensure the simplicity of the analysis, 140/90 mmHg was basically used as a 
criterion of adherence in the present study, although JSH 2000 provided different 
thresholds by age of patients as mentioned above. 
A multiple logistic regression analysis was performed to investigate factors 
associated with clinic physicians’ non-adherence to the guideline recommendations. The 
dependent variable was a binary variable taking one if they preferred 160/95 mmHg as 
the diagnostic criteria of high blood pressure in 2004, and zero if they answered that 
140/90 mmHg was appropriate. Explanatory variables were respondents’ age, the 
number of hypertensive outpatients consulted per day, and awareness of JSH 2000. To 
obtain the daily number of hypertensive outpatients, the product of the number of 
outpatients per day and the percentage of hypertensive patients was rounded to the 
nearest whole number. The four variables of awareness were combined to create an 
independent variable on awareness that consisted four categories: “not recognized or not 
accessed,” “accessed but not familiar,” “familiar but not utilized yet,” and “utilized (the 
reference category).” 
The chi-squared test was used to test the null hypothesis of no difference in 
awareness between the two surveys. Wald tests were employed to test the null 
hypothesis of no difference in the estimated associations of awareness with adherence 
between the categories of awareness. A P-value less than 0.05 was considered to 
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indicate statistical significance. All analyses were implemented with Stata/MP version 
10.1 (StataCorp LP, College Station, TX, USA). 
 
3.3 Results 
 
Characteristics of survey participants 
Response rates of the surveys in 2000 and 2004 were 18.7% (896/4,800) and 
14.3% (1,425/10,000), respectively. Table 3.1 summarizes the characteristics of the 
respondents from each survey. The mean age of participants was 57.0 years old in both 
surveys with a standard deviation of 12.2 and 12.6 years in 2000 and 2004, respectively. 
The median number of outpatients consulted per day was 50 in both surveys 
(interquartile ranges, IQR: 30–80 in 2000 and 30–65 in 2004). The median percentage 
of hypertensive patients from all outpatients was 30% in both surveys with an IQR of 
15–50% in 2000 and 20–50% in 2004. The median number of hypertensive patients 
consulted per day was 14 in both surveys (IQR: 6–24 in 2000 and 8–21 in 2004). The 
median percentage of people aged 65 years or over out of all hypertensive outpatients 
was 65% (IQR: 30–80%) in 2000, and more than 70% of the hypertensive patients were 
aged 65 or over in nearly half of the clinics (384/791, 48.5%). 
 
Awareness of JSH 2000 
The survey in 2000 revealed that, of 822 respondents, 43.2% (95% CI: 39.8–
46.6%) knew that the guideline would soon be published and wanted to use it in clinical 
practice, 20.0% (95% CI: 17.4–22.8%) had heard of it but were not yet sure whether 
they would use it in clinical practice, 34.8% (95% CI: 31.6–38.1%) did not know about 
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the announcement of the guideline but might like to read it and consider whether to 
introduce it in clinical practice, and 2.1% (95% CI: 1.3–3.3%) had never heard of the 
guideline and had no interest in it. In total, 63.1% of clinic physicians (95% CI: 59.8–
66.4%) were aware of the guideline’s announcement being scheduled in 2000. 
The survey in 2004 showed that 94.4% (1,321/1,400, 95% CI: 93.0–95.5%) 
knew the publication of JSH 2000, 87.0% (1,201/1,381, 95% CI: 85.1–88.6%) had read 
it, 81.5% (1,120/1,374, 95% CI: 79.4–83.5%) had understood its recommendations, and 
68.6% (932/1,359, 95% CI: 66.1–71.0%) had applied them in clinical practice. The 
level of recognition of the guideline among clinic physicians was significantly different 
between the two surveys (63.1% vs. 94.4%, p<0.001). 
 
Adherence to recommendations on treatment of hypertension 
The 2000 survey demonstrated that, for low-risk hypertension in the 140–
149/90–94 mmHg category and with no complications, 64.7% (95% CI: 61.3–67.9%) of 
the 812 respondents conducted non-pharmacological therapies at their facilities, 16.9% 
(95% CI: 14.4–19.6%) referred these patients to other facilities such as community 
health centers and municipalities for lifestyle modifications, and 11.2% (95% CI: 9.2–
13.6%) prescribed medicines. For low-risk hypertension in the 150–159/95–99 mmHg 
category and with no complications, 71.7% (95% CI: 68.5–74.7%) of 807 respondents 
prescribed medicines, 21.8% (95% CI: 19.1–24.8%) gave instructions on lifestyle 
change at their facilities and 2.5% (95% CI: 1.6–3.8%) did so through referrals to other 
facilities. Lifestyle modification was adopted in total by 81.5% (95% CI: 78.7–84.1%) 
for the 140–149/90–94 mmHg category and 24.3% (95% CI: 21.5–27.4%) for the 150–
159/95–99 mmHg category. 
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In the 2004 survey, as major management strategies for mild hypertension 
(multiple answers), 80.1% (95% CI: 77.9–82.2%) of the 1,384 respondents conducted 
lifestyle modification, 22.6% (95% CI: 20.5–24.9%) prescribed medicines, 9.8% (95% 
CI: 8.4–11.5%) employed dietitians or public health nurses to offer lifestyle 
modification, 2.5% (95% CI: 1.8–3.5%) referred patients to other healthcare providers 
because they could not treat them at their facilities, and 6.4% (95% CI: 5.2–7.8%) did 
nothing. Instructions on lifestyle change was provided in total by 85.5% (95% CI: 83.5–
87.2%) of clinic physicians in 2004. 
 
Adherence to recommendations on the threshold of blood pressure 
Table 3.2 provides the ranking of thresholds of blood pressure to initiate 
antihypertensive medications for uncomplicated hypertension in the 2000 survey. The 
top three thresholds for 50-year-old patients in total accounted for half of the 796 valid 
responses: 150/90 mmHg (19.1%, 95% CI: 16.5–22.0%), 150/95 mmHg (16.0%, 95% 
CI: 13.6–18.7%), and 160/95 mmHg (15.1%, 95% CI: 12.8–17.7%). The recommended 
threshold for this age group by JSH 2000, i.e. 140/90 mmHg, was supported only by 
6.4% (95% CI: 4.9–8.3%). For 80-year-old patients (n=784), the most popular 
thresholds were 160/100 mmHg (16.8%, 95% CI: 14.4–19.6%), 160/95 mmHg (16.3%, 
95% CI: 13.9–19.1%), and 160/90 mmHg (13.1%, 95% CI: 10.9–15.7%). 
The survey in 2004 showed that 68.9% of 1,388 respondents (95% CI: 66.4–
71.3%) agreed with 140/90 mmHg as the threshold of blood pressure for the diagnosis 
of hypertension, 17.1% (95% CI: 15.2–19.1%) preferred 160/95 mmHg, and 14.0% 
(95% CI: 12.3–16.0%) were not sure. Table 3.3 summarizes the results from the 
multiple logistic regression analysis on factors associated with the choice of 160/95 
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mmHg. Physicians were more likely to prefer the old criteria if they were older (OR: 
1.016, 95% CI: 1.003–1.028, p=0.014), or if the number of hypertensive outpatients 
consulted per day was smaller (OR: 0.987, 95%CI: 0.974–1.000, p=0.044). Moreover, 
physicians’ awareness of the guideline had a significantly negative association with 
their preference of 160/95 mmHg: compared to physicians who had applied the 
guideline recommendations in clinical practice, the likelihood of favoring the old 
criteria was significantly higher among those who had neither heard of nor read them 
(OR: 1.690, 95% CI: 1.068–2.674, p=0.025), those who had read them but did not 
understand the content (OR: 2.869, 95% CI: 1.591–5.174, p<0.001), and those who 
were familiar with the recommendations but had never used them in clinical practice 
(OR: 3.073, 95% CI: 2.046–4.615, p<0.001). The odds ratios were significantly 
different between “not recognized or not accessed” and “familiar but not utilized” 
(p=0.031), while the differences were not significant between adjacent categories 
(p=0.134 between “not recognized or not accessed” and “accessed but not familiar,” and 
p=0.837 between “accessed but not familiar” and “familiar but not utilized”). 
 
3.4 Discussion 
 
This study is the first to assess awareness of and adherence to recommendations 
of JSH 2000 among clinic physicians across the country over time. In the four years 
since its announcement, the guideline has been widely recognized and adopted by clinic 
physicians. Although considerable adherence to its recommendations has been achieved, 
noncompliance with the new definition of hypertension was not negligible, and it was 
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associated with clinic physicians’ age, the number of hypertensive outpatients consulted 
per day, and awareness of the guideline. 
Awareness of JSH 2000 had substantially increased among clinic physicians 
during four years between the two surveys. Although a number of factors may have 
contributed to this success, it remains to be seen whether staging of continuing 
education conferences by the Japanese Society of Hypertension was effective in 
promoting awareness of guideline recommendations in clinical practice (Ogihara et al. 
2009). A randomized controlled study in Germany showed that poor participation let it 
infeasible to evaluate the effectiveness of standardized educational seminars for 
improving awareness of the German Hypertension Society’s guidelines (Hagemeister et 
al. 2008). In addition, the high rate of access to JSH 2000 in the present study was 
almost comparable to the figures relating to the guidelines of the British Hypertension 
Society. A web-based physician survey in 2006 demonstrated that the percentage of 
general practitioners who had read each of seven specified recommendations ranged 
from 52% to 99% (Heneghan et al. 2007). 
The present study revealed that a majority of clinic physicians knew the 
recommendations of JSH 2000. This familiarity rate, however, should be interpreted 
with caution, because it depends on the definitions and measurement methods. An 
example of a study based on a relatively similar questioning technique to that of the 
present study was a postal survey to physicians conducted in the United States in 1996, 
which assessed the familiarity rate of the JNC V guidelines to be as low as 60% 
(Hyman and Pavlik 2000). On the other hand, a few studies have employed counting the 
number of correct answers to clinically-oriented questions, in order to enhance the 
objectivity of the measurement of familiarity. For instance, studies undertaken in Italy 
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and Germany defined awareness as knowledge conforming to guidelines and measured 
it by the number of answers that were in agreement with guideline recommendations, 
which notionally corresponds to familiarity in the present study (Cuspidi et al. 2003; 
Hagemeister et al. 2001; Hagemeister et al. 2008). They revealed that the level of 
familiarity was fairly low: the recommendations of the 1999 WHO/ISH guidelines were 
understood adequately only by 20% in Italy (Cuspidi et al. 2003), while the figure for 
the German guidelines was 24% in 2000 and 37% in 2005 (Hagemeister et al. 2001; 
Hagemeister et al. 2008). In the Italian study, however, more than 80% of respondents 
stated that they were familiar with guidelines (Cuspidi et al. 2003), which was 
comparable to the figure of the present study. These results indicate that a substantial 
discrepancy exists between objectively assessed knowledge and self-reported familiarity. 
Familiarity with JSH 2000 among clinic physicians may therefore be overestimated in 
the present study, which suggests the need for the introduction of objective 
measurements of knowledge to assess familiarity with guidelines in future studies. 
Lifestyle modification has been widely adopted as a primary strategy for the 
management of mild or low-risk hypertension in Japan. This compared favorably with 
studies on adherence to other hypertension guidelines. For example, although it is old, a 
study based on a review of medical records in Canada showed that, during the two years 
after the Canadian Hypertension Society had produced clinical practice guidelines in 
1993, instructions on lifestyle change were given only to half of patients who had been 
newly diagnosed with hypertension (McAlister et al. 1997). Moreover, a survey of 
patients in Italy in 2001 revealed that only 10% of them had received a full clinical and 
laboratory evaluation for the diagnosis of hypertension as recommended by the 1999 
WHO/ISH guidelines (Cuspidi et al. 2002), although this is not directly comparable 
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with the present study due to different methodologies. A considerably high adherence to 
guideline recommendations on lifestyle modification was achieved among general 
practitioners in the United Kingdom: the electronic survey demonstrated that 90% of 
them agreed with provision of verbal advice on lifestyle change and 85% introduced it 
into their own practice in 2006 (Heneghan et al. 2007). 
Adherence to the recommendation of JSH 2000 on the classification of blood 
pressures substantially improved after 2000, while a considerable fraction of clinic 
physicians still opted for the old criteria. The results of the present study further pointed 
out that the preference for thresholds of blood pressure was associated with physicians’ 
age, the number of hypertensive outpatients, and their awareness of the guideline 
recommendations. The finding on the association with physicians’ awareness of the 
guidelines was consistent with the result of the mail physician survey in the United 
States in 1996. They revealed that, for middle-aged patients without diabetes, more than 
one third of physicians would not initiate antihypertensive medication unless diastolic 
blood pressures were consistently greater than 95 mmHg, and half of them would not 
start it until systolic blood pressures exceeded 160 mmHg. Physicians who were 
familiar with the JNC V guidelines were more likely to start the pharmacological 
treatment on elderly patients at a lower threshold of blood pressure than those who were 
not (Hyman and Pavlik 2000) 
Old age of patients may be a potential important factor of the preference for the 
old threshold of blood pressures among clinic physicians. Few studies have examined 
reasons for not adhering to the recommended classification of blood pressures, while a 
recent survey on publicly employed general practitioners in southern Sweden 
demonstrated that old age of patients was one of major reasons for not starting 
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pharmacological treatment immediately, and half of them waited until 170/100 mmHg 
(Midlov et al. 2008). In JSH 2000, as described above, thresholds for initiating 
antihypertensive medications on elderly patients were set at higher levels than that in 
the young and middle-aged who were less likely to have target-organ damage. This 
partly reflects the facts that, at the time of the publication of JSH 2000, there was not 
sufficient evidence yet to support lower thresholds for starting prescription of blood 
pressure lowering drugs for the elderly, and it was generally considered in clinical 
practice that the elderly should not undergo excessive decreases in blood pressure. 
Although the 2004 survey did not ask respondents about the age distribution of their 
hypertensive patients, given that other basic characteristics of the participants were 
almost the same with those in the 2000 survey, it is possible to speculate that the elderly 
accounted for a majority of hypertensive patients at many of participating clinics in the 
2004 survey. Further investigation is required with regard to the effects of the age 
structure of hypertensive outpatients on the clinic physicians’ preference for a blood 
pressure threshold. 
After JSH 2000, the Japanese Society of Hypertension has revised the guidelines 
twice in 2004 and 2009. JSH 2009 proposed 140/90 mmHg as a threshold of blood 
pressure for starting antihypertensive medication to all patients including the elderly. 
Following the accumulation of new evidence on the efficacy of blood pressure lowering 
drugs for hypertension in the elderly, the guidelines recommended aggressive 
antihypertensive treatment for elderly patients to reduce the risk of mortality from and 
incidence of stroke and ischemic heart diseases. Moreover, in JSH 2009 metabolic 
syndrome and chronic kidney disease have been added as a part of the prognostic 
factors to stratify hypertension according to the risks of cardiovascular and 
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cerebrovascular diseases. In the context of non-adherence of physicians examined above, 
it may be a challenge how to promote their understanding of these revised 
recommendations. One of effective strategies may be to reinforce the efforts on 
continuing educational seminars, particularly for those who have not been very aware of 
the past guidelines, are older, or have the moderate number of hypertensive patients. 
Future studies should keep monitoring adherence of clinic physicians to the guideline 
recommendations to assess the outcomes of the current guidelines. 
The present study had several limitations that need to be considered in the 
interpretation of its findings. First, the response rates to the surveys used in this study 
were considerably low. Although the sampling design was intended to obtain 
representative samples of clinic physicians in Japan, the samples might be still biased to 
those who were enthusiastic and dedicated to the management of hypertension. Sending 
timely reminders to sampled physicians would be one of the approaches for increasing 
response rates in future studies. In fact, three or more reminders by mail achieved 
responses from 47% and 34% of the sampled physicians in the German survey in 1999–
2001 and the US survey in 1996, respectively (Hagemeister et al. 2001; Hyman and 
Pavlik 2000). Second, as this study relied on self-reports of clinic physicians, findings 
might be subject to non-random measurement errors. The use of objective 
measurements such as prescription and drug-dispensing data and medical records would 
help improve the accuracy of data and decrease potential bias in the estimates. In 
addition, as mentioned above, even the use of clinically-oriented questions based on 
guideline recommendations would perform better than simply asking participants to 
self-report on their awareness of hypertension guidelines. Third, there may be a 
potential systematic bias in direct comparison of the preference for a blood pressure 
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threshold and the management of mild hypertension between the 2000 survey and the 
2004 survey, because they were based on questions that were not identical to each other. 
Lastly, this study does not provide any evidence on the relationship between adherence 
to the guidelines and control of blood pressure. Linkage with medical records or 
examination surveys will help quantify outcomes and evaluate the quality of guideline 
recommendations in future research. It can however be safely argued that the nature of 
this study as the first assessment of clinic physicians’ awareness of JSH 2000 and 
adherence to its recommendations outweighs these disadvantages. 
In conclusion, JSH 2000 has achieved a substantial improvement in clinic 
physicians’ awareness of and adherence to its recommendations on the management of 
low-risk hypertension. A considerable number of clinic physicians, however, still 
preferred 160/95 mmHg as a diagnostic threshold of hypertension. One of the strategies 
to further enhance their compliance with future revised guidelines would be to identify 
and implement effective ways for the guidelines to be disseminated to clinic physicians 
who are older, who manage a relatively small number of hypertensive outpatients, and 
who have not read, understood, or introduced guideline recommendations into their 
practice yet. In particular, future research needs to investigate scientifically what kinds 
of interventions would be effective as regards encouraging the comprehension and 
introduction of guideline recommendations in clinical practice in the Japanese context. 
This is an essential task as the increased adherence of physicians to evidence-based 
medicine would eventually enhance the quality of care for hypertension through the 
effective utilization of revised editions of these guidelines. 
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Table 3.1 Characteristics of respondents to physician surveys in 2000 and 2004 
 
Characteristics 2000   2004   
 n   n   
Age in years, mean (SD) 847 57.0 (12.2) 1,394 57.0 (12.6) 
Number of patients per day 829 50 (30–80) 1,337 50 (30–65)
% of HT patients 806 30 (15–50) 1,331 30 (20–50)
Number of HT patients per day 793 14 (6–24) 1,283 14 (8–21) 
% of those aged ≥ 65 in HT 
patients 
791 65 (30–80) NA   
HT, hypertensive; NA, not available; SD, standard deviation. 
Values are medians with interquartile ranges in parentheses unless otherwise stated. 
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Table 3.2 Threshold of blood pressure to start antihypertensive medications for 
uncomplicated hypertension, by age of patients, the survey in 2000 
 
Age of patients SBP/DBP, mmHg % 95% CI 
50 years old  150/90 19.1 16.5–22.0 
(n=796) 150/95 16.0 13.6–18.7 
 160/95 15.1 12.8–17.7 
 160/100 13.8 11.6–16.4 
 160/90 10.2 8.3–12.5 
 140/90 6.4 4.9–8.3 
 Others 19.5 16.9–22.4 
80 years old 160/100 16.8 14.4–19.6 
(n=784) 160/95 16.3 13.9–19.1 
 160/90 13.1 10.9–15.7 
 170/100 11.7 9.7–14.2 
 150/90 6.6 5.1–8.6 
 180/100 6.4 4.9–8.3 
 Others 29.0 25.9–32.2 
CI, confidence interval; DBP, diastolic blood pressure; SBP, systolic blood pressure. 
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Table 3.3 Odds ratios for the choice of 160/95 mmHg as a diagnostic threshold of 
hypertension in association with respondents’ characteristics and awareness of the 
Japanese Society of Hypertension Guidelines for the Management of Hypertension 
2000, the survey in 2004 (n = 1,077) 
 
Covariates OR 95% CI p-value 
Age (years) 1.016 1.003–1.028 0.014 
Number of HT outpatients consulted per day 0.987 0.974–1.000 0.044 
Awareness    
Not recognized or not accessed 1.690 1.068–2.674 0.025 
Accessed but not familiar 2.869 1.591–5.175 <0.001 
Familiar but not utilized 3.073 2.046–4.615 <0.001 
Utilized 1.000   
CI, confidence interval; HT, hypertensive; OR, odds ratio. 
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CHAPTER 4 
Conclusions 
 
 
From the standpoints of the public and the clinical practice, this thesis studied 
two important issues related to the control of blood pressure of the population in Japan: 
1) contributions of the improvements in life-style related factors and antihypertensive 
treatment to the decreasing trend of mean blood pressure in the general population; and 
2) changes in clinic physicians’ attitudes toward evidence-based medicine on the 
management of hypertension after the publication of the first official clinical guidelines. 
In these final remarks, I will focus on some of the major conclusions, the policy 
relevance of this work and directions for future research. 
 
4.1 Control of population blood pressure in Japan 
 
One conclusion that has emerged from these studies is that the situation has 
improved as regards the control of blood pressure in the community and clinical 
practice over time. Although a considerable portion remains to be explained, Chapter 2 
showed that the decrease in mean SBP between the late 1980s and the early 2000s was 
partly attributable to the increased coverage of antihypertensive medications, a reduced 
intake of dietary sodium, and a decline in mean BMI of young women. These changes 
may in part reflect the strenuous and dedicated efforts of experts in the community and 
medical practice over the past few decades to improve the management of blood 
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pressure and related diseases. Moreover, Chapter 3 revealed that an increasing number 
of clinic physicians became aware of and adhered to the recommendations of JSH 2000 
during the four years following its announcement in 2000. The clinical guidelines are 
useful tools for educating clinic physicians on the importance of practicing evidence-
based medicine for the diagnosis and treatment of hypertension, although further 
investigation is necessary to evaluate the effectiveness of these clinical guidelines in 
improving the control of blood pressure. 
For further improvement in the control of population blood pressure in Japan, 
this thesis proposes a framework of strategies for primary prevention in the community 
and secondary prevention in clinical practice (Figure 4.1). In the community, lowering 
dietary sodium intake and body weight management are the key population approaches 
for primary prevention of hypertension, while targeting high-risk groups such as 
overweight and obese people and alcohol consumers is also essential. 
Reducing salt consumption among the Japanese population is a challenge, 
because it is one of essential seasonings for Japanese dishes. Although average daily 
salt intake in Japan has been decreasing, it was still substantial in 2008, recording 11.9 
grams in men and 10.1 grams in women (MHLW 2009c). These figures are far above 
the official target for 2010–2014, that is, 9 and 7.5 grams in men and women, 
respectively (MHLW 2009b). Given that reduction in daily salt intake made a 
significant contribution to the decreasing trends in mean SBP, steady efforts are 
necessary to enhance the awareness of the public about the dangers of an excess salt 
intake and to motivate them to implement salt restriction. It would be particularly 
helpful to encourage restaurants and grocery stores to provide calorie and nutrition 
  66
information on menus and labels, so that consumers recognize the quantity of salt they 
are eating. 
The growing trend of overweight and obesity, especially in young men, is one of 
the most serious health problems in Japan today. The prevalence of overweight and 
obesity in men has been rising in the 2000s (MHLW 2008). This trend will also increase 
the future burden of disease through development of metabolic disorders such as insulin 
resistance, glucose intolerance, and dyslipidemia as well as hypertension should it go 
unchecked. Continued efforts are necessary to control obesity-related hypertension 
through targeting at obese individuals and promoting body weight management in the 
general population. Extensive research is urgently needed to explore the balance 
between caloric intake and energy expenditure at the population level (Bleich, Cutler, 
Murray and Adams 2008) and to identify bottlenecks to be eliminated for reversing the 
obesity trend. 
Alcohol drinking remains to be a serious problem when it comes to the control 
of blood pressure in Japan. The prevalence of alcohol consumption has been persistently 
high among men and it has been rising among women, although it has been 
acknowledged for years that cessation or moderation of alcohol intake is important for 
the management of blood pressure in Japan (Ueshima et al. 1992). Decreasing the 
prevalence of alcohol consumption is an extremely difficult challenge, because the 
population is generally tolerant as regards drinking: it is has deep cultural roots in 
Japanese society and is a useful tool for socialization and relieving the stress emanating 
from human relationships. Even worse in terms of blood pressure control, alcohol 
beverages are available at 24-hour convenience stores today. Something therefore has to 
be fundamentally changed for reducing the prevalence of drinking. The government 
  67
should at the very least revise and strengthen policy measures that promote moderate 
drinking or even abstention and  increase the recognition among the public about 
alcohol as being a substance which is harmful to health. 
Regarding the management of hypertension in clinical practice, promotion of 
evidence-based medicine in clinical practice is important to encourage early detection 
and prescription of appropriate therapies (Figure 4.1). Coverage of blood-pressure 
lowering drugs is still insufficient and stayed at around 50% in 2006 (MHLW 2009a). 
The other half of hypertensive patients fall under one of three categories: those left 
undiagnosed; those prescribed with non-pharmacological therapies only; or those who 
are not following their prescribed medication. In addition, Chapter 3 showed that quite a 
few clinic physicians still disagreed with or had never implemented the guideline’s 
recommendations in the four years since its publication. One way of enhancing blood 
pressure control of the population would be, therefore, to further disseminate the 
guidelines to encourage early detection and appropriate treatment of hypertension. 
Given that the elderly accounted for 70% of people having systolic hypertension in 
2006 (MHLW 2009a), renewed efforts are required to promote the understanding of 
physicians about the evidence on aggressive antihypertensive treatment on the elderly 
patients as recommended by JSH 2009. The strict management of elevated blood 
pressure in the older population would eventually contribute to resuming the progress in 
the control of population blood pressure. 
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4.2 Methodological directions for future research 
 
This thesis lays out two methodological directions for future research on the 
control of population blood pressure in Japan: 1) the improvement in the quality of 
household survey data through extensive collection of key information and refinement 
of measurement methods of biomarkers of physiological risks; and 2) the introduction 
of multidisciplinary approaches to the analysis of health survey data. 
 
Improvement in the quality of household survey data 
Extensive collection of key information 
Japan is one of a few countries that have accumulated health information 
through a series of household surveys conducted on nationally representative samples. 
However, a number of essential variables are still lacking, which poses a fundamental 
obstacle to the explanation of variances in outcomes of interest. Chapter 2 pointed out 
that the availability of important covariates should be increased to improve the capacity 
of the model to account for the decline of population blood pressure in Japan. It is 
difficult to revise policies for blood pressure control, when a substantial part of the 
change remains unexplained. 
Although the NNS was redesigned as the National Health and Nutrition Survey 
(NHNS) in 2003, the survey still doesn’t ask basic socioeconomic characteristics, such 
as those pertaining to income, occupation, marital status, and educational background. 
Given that these items are essential information of respondents for quantitative analyses 
on any topics relevant to health, this drawback may be detrimental as a national 
household health survey. In fact, they are usually included in the questionnaires of 
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major household health surveys in other countries, such as the National Health 
Interview Survey in the United States and the Demographic and Health Surveys. In this 
era of growing public recognition of privacy, those involved in the survey design should 
reconsider strategies of ensuring confidentiality for the benefit of respondents, so as to 
incorporate these sensitive topics effectively into the annual household surveys. 
Another important item that is not routinely available is past history of 
hypertension. This has been studied only once a decade since 1980 in the National 
Survey of Cardiovascular Diseases (NSCD). Information on past diagnosis is crucial to 
determine whether hypertensive people who are not on medication have never had the 
condition diagnosed (undiagnosed hypertension), or they have ever been diagnosed but 
are not taking blood pressure lowering drugs for some reasons (diagnosed and untreated 
hypertension). Moreover, considering that thresholds of high blood pressure vary 
among clinic physicians as shown in Chapter 3, a number of hypertensive patients may 
be left undiagnosed and consequently untreated. In fact, the 1990 NSCD revealed that 
more than half of Japanese adults who had systolic blood pressure ≥ 140 mmHg or 
diastolic blood pressure ≥ 90 mmHg or were on antihypertensive medication were 
unaware of their condition, while 10–20% of them had been diagnosed but were not 
treated (Sekikawa and Hayakawa 2004). Thus, past history of hypertension should be 
routinely investigated in annual NHNS to explore the current situation of diagnosis and 
treatment, particularly with regard to untreated hypertension. 
 
Refinement of biomarker measurement in household surveys 
Although reliable measurement of biomarkers is essential to assess physiological 
risks of a population, it is not satisfactory yet in national household surveys in Japan. 
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With regard to blood pressure, in the NNS and the NHNS, clinic blood pressure was 
measured only once until 2000, when it started taking two measurements on a single 
visit of respondents. JSH 2009 might provide useful criteria for blood pressure 
measurement in the surveys: the guideline recommends that clinic blood pressures are 
measured at least on a couple of different occasions, so that diagnosis of hypertension is 
based on the average of two stable measurements that have a difference of less than 5 
mmHg (Ogihara et al. 2009). In addition, as discussed in Chapter 2, introduction of 
blood pressure measurement in non-clinical settings, i.e. ambulatory blood pressure 
monitoring and home blood pressure measurement, may help reduce the variability in 
blood pressure readings in the household surveys. 
As regards blood samples, fasting for more than eight hours before a blood test 
is becoming the norm for national household surveys in the world, including the 
National Health and Nutrition Examination Survey in the United States (Centers for 
Disease Control and Prevention 2008). Respondents in the NHNS are, however, only 
encouraged to fast for more than three hours before a blood test (MHLW 2006). A 
number of blood samples may be consequently non-fasting in a strict sense: in fact, only 
3% of participants in the 2000 NSCD had a blood test in more than eight hours after 
eating (MHLW 2003). Non-fasting blood glucose and cholesterol without any 
adjustment will lead to inaccurate assessments of the management of diabetes and 
dyslipidemia. It is therefore urgent to ensure collection of fasting blood samples in the 
NHNS, especially in order to provide reliable and comparable evidence on metabolic 
syndrome. In addition, fasting samples would facilitate application of the global 
framework of comparative risk assessments on fatal and non-fatal health outcomes 
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related to metabolic disorders (Danaei et al. 2009; Danaei, Lawes, Vander Hoorn, 
Murray and Ezzati 2006). 
 
Introduction of multidisciplinary analysis of health survey data 
Another methodological direction for future research is to strengthen national 
health information systems with sound data and sophisticated research frameworks. 
Population health metrics and evaluation research would play a key role in integration 
of public health with existing methodologies from diverse disciplines, such as 
economics and political science, in order to develop the empirical basis for assessment 
of health policies and programs. This interdisciplinary field refers to the science of 
measurement, instruments, and indicators of health outcomes, in an attempt to establish 
a causal link between interventions and effects in both national and global contexts 
(Murray and Frenk 2008). This thesis has demonstrated application of an econometric 
technique to get treatment effects quantified from cross-sectional survey data, which 
had been impossible for conventional approaches of public health research in Japan. In 
addition, a recent study based on cross-sectional surveys employed three analytical 
approaches, i.e. matching, with-versus-without comparison, and differences in 
differences, in order to evaluate the impact of a conditional cash transfer scheme for 
promotion of institutional delivery in India (Lim et al. 2010). This new tide of research 
will stimulate the use of abundant underutilized data for enhancing a knowledge base on 
the control of blood pressure in Japan. 
Finally, as a part of endeavors for improving the management of hypertension, 
we need a clear perspective of contributing with scientific knowledge to the global 
community. It is a duty for one of highly developed economies to share evidence on the 
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assessment of health system performance with policymakers and academics overseas. 
Participation in interactive dialogues and discussions would eventually help us learn 
what is essential in future health policies for population blood pressure control in Japan. 
  73
Secondary prevention 
in clinical practice
Promotion of evidence‐based 
medicine in clinical practice
 Early detection & treatment
Increase coverage of blood‐
pressure lowering drugs
Primary prevention 
in the community
1. Population approach
Body weight control
Reduced dietary sodium intake
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Improved population blood pressure control in Japan
 
Figure 4.1 Strategies for improving population blood pressure control in the 
community and clinical practice in Japan. 
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平成１２年９月 
 
高血圧治療に関するアンケート調査のお願い 
 
 
 
最近、新しい分類での高血圧治療のガイドライン（参考資料）が提案されています。その多くが、こ
れまで境界域血圧としていた血圧領域を軽症高血圧と位置づけています。この背景には、きわめて低い
血圧は別にして、脳卒中や心筋梗塞など高血圧治療の標的疾患の発症率は血圧が低いほど低下する事が
判ったからと考えられます。わが国でも、新たな高血圧ガイドラインが検討されています。 
昨年度｢高血圧と関連疾患の疾病管理の研究｣が行われ、高血圧治療の現状が調査されました。本年度
は研究内容を発展させ、厚生科学研究｢高血圧予防診療法の技術評価に関する研究｣研究班として、日常
の高血圧診療がどのように行われ、今後どのような変化が予測されるかの調査をすることとなりました。 
つきましては、実際に臨床診療を行っている先生方を対象に、高血圧症治療に関するアンケート調査
を実施させていただくことといたしました。ご多忙の折、誠に恐縮ではございますが、調査の趣旨をご
理解いただき、次頁の設問にお答えいただきたく、お願い申し上げます。 
なお、昨年度にも同様の趣旨で調査が実施されましたが、今後の研究にとって非常に重要な基礎デー
タとなることから、より多くの先生方からご意見をうかがう必要があるため、再度、調査を実施させて
いただくこととなりました。 
ご記入が終わりました調査票は同封の封筒に入れ、9 月 30 日までにご投函をお願いいたします。 
なお、調査の回答結果は、すべて統計的に処理し、個人のデータが公表されることはありません。ま
た、本研究の目的以外に使用されることはございません。 
 
厚生科学研究｢高血圧予防診療法の技術評価に関する研究｣研究班 
国立医療・病院管理研究所医療政策研究部長 長谷川敏彦 
慶應義塾大学医学部長           猿田 享男 
 
 
 
 
１．調査票には、黒あるいは青のボールペンなどでご記入下さい。 
２．回答される際に、「その他」を選択された場合には、（  ）内に具体的な内容をご記入下さい。 
３．そのほか、本調査に関して不明な点などございましたら、下記の連絡先までお問い合わせ下さい。
なお、担当者が不在のことが多いため、問い合わせはできればファクシミリにてお願いいたします。 
 
【問い合わせ先】 
厚生科学研究医療技術評価総合研究事業｢高血圧予防診療法の技術評価に関する研究｣事務局 
国立医療・病院管理研究所医療政策研究部長 長谷川敏彦 
Fax：03-3202-6853（Tel：03-3203-4821） 
 
 
 
85
Appendix 1. Survey questionnaire (2000) 
(Reprinted with permission of Toshihiko Hasegawa)
 
1 主な勤務先の都道府県名をご記入ください。  都道府県名 
 
2 ご回答をいただく先生についてうかがいます。 
（１）勤務形態 ア 勤務医  イ 開業医 （２）年齢       歳 
（３）従事されている主な診療科１つに○をつけて下さい。 
ア．内科  イ．消化器科（胃腸科） ウ．循環器科  エ．呼吸器科    オ．精神科 
カ．神経科（神経内科）        キ．心療内科  ク．リウマチ科    ケ．アレルギー科 
コ．小児科   サ．その他 (               科) 
 
3 先生の外来での１日平均診察人数及び高血圧症患者の割合をお教え下さい。 
（１）平均患者数      （２）高血圧症患者の割合  
 人／日  ％ →うち 65歳以上の割合       ％ 
 
4 血圧降下薬を使用せず、生活指導のみの高血圧治療（非薬物療法）を行っている患者さんの高血圧治療に
占める割合はどの程度ですか。         ％ 
 
5 高血圧症治療に関する新しいガイドライン（参考資料）が米国及び WHO で作成され提案されていますが、
ご存知ですか。１つに○をつけて下さい。 
ア 内容まで良く知っている  イ あることは知っている  ウ 知らない 
 
6 参考資料にあるような高血圧症の管理方法についてどのようにお考えますか。１つに○をつけて下さい。 
ア 合理的であり、臨床の場に導入している 
イ 理想的であるが、現実的な臨床の場では実行できない 
ウ 臨床の状況を知らない空想的なものであり、考慮に値しない 
エ その他ご記入ください（                ） 
 
7 日本でも先日高血圧の新しいガイドラインが示されましたが、新しいガイドラインについて先生のお考え
に最も近いものを１つ選んで○をつけて下さい。 
ア 新しいガイドラインが示されたのは知っており、今後の診療の参考にしたい 
イ 新しいガイドラインが示されたのは知っているが、実際の診療で活用するかは未定である 
ウ 新しいガイドラインが示されたのは知らないが、内容によっては今後の診療に活用したい 
エ 新しいガイドラインが示されたのは知らないし、内容についても興味はない 
 
8 家庭自己血圧測定による患者の自己管理についてお聞きします。 
8-1 先生のお考えに最も近いものを１つ選んで○をつけて下さい。 
ア 大変有用で重要な治療法と思う  イ あまり有用な方法とは思わない  ウ わからない 
8-2 先生の診療では活用されていますか。あてはまるものを１つ選んで○をつけて下さい。 
ア 積極的に患者に勧めて活用してる  イ 患者によっては活用してる  ウ 使っていない 
 
9 合併症のない高血圧症（140－159mmHg／90－99mmHg）の患者さんの治療・管理についてお聞きします。 
9-1 (1)、(2)のそれぞれの場合について先生のお考えに最も近いものを１つを下の四角のアからオまでの
中から選んで、（ ）にご記入ください。 
(1) 140－149mmHg／90－94mmHg の患者さんの場合   
(2) 150－159mmHg／95－99mmHg の患者さんの場合   
ア 薬物療法を主体とした治療・管理対象となる 
イ 医療機関の非薬物療法を主体とした治療・管理対象となる 
ウ 医療機関以外の非薬物療法を主体とした治療・管理対象となる 
  （例．保健所や市町村等が行う訪問指導、健康教室、食事・運動指導等） 
エ 上記のどれともいえない 
オ 治療・管理の対象にならない 
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9-2 ｢ア 薬物療法を主体とした治療・管理対象となる｣｢エ どちらともいえない｣と回答された方にうか
がいます。非薬物治療を実施しない理由について主なものを１つ選んで、番号に○をつけて下さい。 
ア 診療時間が短い      イ 診療報酬の体系上、経済的に不利になる 
ウ 必要な人材がいない    エ 患者が望まない 
オ 薬物を用いる方が効果的  カ その他（         ） 
9-3 先生の診療されている高血圧症患者のうち、(1)、(2)のような患者さんは何％くらいを占めますか。 
(1) 140－149mmHg／90－94mmHg の患者さん      ％ 
(2) 150－159mmHg／95－99mmHg の患者さん      ％ 
 
10 合併症のない高血圧症（160mmHg／100 mmHg をやや超える）の患者さんの薬物療法に対しては、最
初にどのような血圧降下薬を使っておられますか。 
10-1 いわゆる第一選択薬（ファーストチョイス）について３つまで選んで○をつけ、最も重要な第一選択
薬１つに◎をつけて下さい。 
ア 降圧利尿薬        イ ACE 阻害薬   ウ カルシウム拮抗薬 
エ β（交感神経）遮断薬   オ α遮断薬     カ AⅡ受容体拮抗薬 
キ その他（                ）   ク 特に決めていない 
10-2 年齢によりファーストチョイスを使い分けていますか。 
ア 使い分けている   イ 使い分けはしない 
 
11 血圧降下薬を用いる高血圧症治療方法の具体例についてうかがいます。 
11-1 合併症がない場合、薬物療法が必要と考えるケースの血圧値をご記入ください。 
①ケースが 50 歳の場合 最大血圧    mmHg 以上、又は最小血圧    mmHg 以上 
②ケースが 80 歳の場合 最大血圧    mmHg 以上、又は最小血圧    mmHg 以上 
11-2 上記のそれぞれのケースについて、降圧の最終的な目標となる血圧値をお教えください 
①ケースが 50 歳の場合 最大血圧    mmHg 以下、かつ最小血圧    mmHg 以下 
②ケースが 80 歳の場合 最大血圧    mmHg 以下、かつ最小血圧    mmHg 以下 
 
12 先生が現在治療・管理されている高血圧症の患者さんについてうかがいます。 
12-1 先生の指示に従っている患者さんの割合はどの程度ですか。｢定期的な通院｣、｢適切な服薬｣、｢適切
な食事・運動への取組み｣のそれぞれについてお答えください。 
(1)定期的な通院    ％ (2)適切な服薬  ％ (3)適切な食事・運動の取組み  ％ 
12-2 ｢定期的な通院｣、｢適切な服薬｣、｢適切な食事・運動への取組み｣などができない患者さんに 
対する先生の主な対応について重要なものを３つまで選んで、番号に○をつけて下さい。 
ア 来院時に口頭で先生から直接注意する  イ 注意を促す手紙をだす 
ウ 担当の看護婦等から電話で連絡させる  エ 患者の家族を教育する 
オ 教室・サークル等への参加を勧める   カ パンフレット、ビデオを用いて指導する 
キ 服薬用の入れ物を工夫する       ク 家庭用血圧計での測定を勧める 
ケ 指導方法を変える（薬物治療とする）  コ 指導方法を変える（非薬物治療とする） 
サ 栄養士等とのチームで対応する     シ 専門施設等を紹介する 
ス 患者の通いやすい他の施設を紹介する  セ その他（            ）   
ソ 患者の自主性に任せ、特に何もしない  
12-3 安定期に入った高血圧症の治療において、医学的に適切な通院間隔はどの程度でしょうか。 
先生のお考えに最も近いものを１つ選んで○をつけて下さい。 
ア 毎週      イ ２週間に１度   ウ １か月に１度  エ ２か月に１度 
オ ３か月に１度  カ ６か月に 1 度   キ もっと長い間隔   
 
ご協力ありがとうございました。 
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【参考資料】 
 
ＷＨＯ-ＩＳＨで示された血圧レベルの診断と分類 
分 類 収縮期血圧 拡張期血圧 
至適血圧 120mmHg 未満かつ 80mmHg 未満 
正常血圧 130mmHg 未満かつ 85mmHg 未満 
正常高値血圧 130－139mmHg 85－89mmHg 
グレード１高血圧（軽症） 
 （サブグループ：境界域高血圧） 
140－159mmHg 
（140－149mmHg） 
90－99mmHg 
（90－94mmHg） 
グレード２高血圧（中等症） 160－179mmHg 100－109mmHg 
グレード３高血圧（重症） 180mmHg 以上 110mmHg 以上 
＊収縮期血圧と拡張期血圧が異なる分類に該当する場合、より高いほうの分類を採用します。 
 
 血圧の分類別の管理方法 
分 類 経過観察 治 療 
至適血圧 － － 
正常血圧 ２年に 1 度以上の確認 － 
正常高値血圧 １年に１度以上の確認 － 
グレード１高血圧（軽症） ２か月以内の確認 
６~12 か月の非薬物療法 
（正常高値まで下がらない場
合、血圧降下薬を併用） 
グレード２高血圧（中等症） １か月以内の診察 薬物療法 
グレード３高血圧（重症） １週間以内の診察 薬物療法 
＊なお、血圧レベルと心血管系リスクとの間には連続した相関があり、高血圧の定義は本質的に任意なものであ
ることから、種々の診断基準の間で定義が異なってきました。そこで、現在では、世界中の臨床医の混乱を避
け統一的な基準とするために、WHO-ISHガイドライン委員会は上のような米国合同委員会による高血圧の診断基
準ならびに分類を基本的に受け入れています。 
88
平成１６年１月 
 
ガイドラインに関するアンケート調査のお願い 
 
 
最近、日進月歩の医療界では、診療ガイドラインの重要性が注目されています。「最新の 
科学的根拠（ＥＢＭ手法）に基づいた」診療ガイドラインを用いることにより、専門でない方
もより良い医療を行うことが可能になります。 
各学会では、厚生労働省の研究費の支援を得るなどして、診療ガイドライン作成に積極的に
取り組んでいます。しかし、これらの診療ガイドラインも、皆様のお役に立つためには「使い
やすく」「分かりやすい」ものでなければなりません。そこで、第一線でご活躍の診療所の 
先生方に診療ガイドラインについてご意見をお聞かせいただき、診療ガイドラインをより良く
するきっかけにしようとアンケート調査を企画いたしました。 
研究班では、診療ガイドラインを作成した先生方にも併せてアンケート調査を実施しており
ます。作成したグループに、今回ご回答いただいた先生方のお考えをお伝えする予定にして 
おります。ご多忙の折、誠に恐縮でございますが、診療ガイドラインを改良し、最終的には 
日本国民の健康を向上させるため、この調査にご協力いただきたく存じます。 
なお、ご回答はコンピュータで統計的に処理され、個人のデータが公表されることはござい
ません。また、本研究の目的以外に使用されることもございません。この調査は、厚生労働科
学研究｢診療ガイドラインの評価に関する研究｣（主任研究者 長谷川友紀 東邦大学助教授）の
一環として行われています。 
ご記入済みの調査票は、同封の封筒にお入れいただき、2月 29日までにご投函下さい。 
 
厚生労働科学研究｢診療ガイドラインの評価に関する研究｣研究班 
国立保健医療科学院（旧国立医療・病院管理研究所） 
政策科学部長 長谷川敏彦 
 
１．調査票には、黒あるいは青のボールペンなどでご記入下さい。 
２．当てはまる選択肢の番号を○で囲む、またはカッコや四角に数字をご記入下さい。「その他」を選択
された場合には、（  ）内に具体的な内容をご記入下さい。 
３．その他、本調査に関してご不明な点がございましたら、下記の連絡先までお問い合わせ下さい。 
ファクシミリの方が確実かと存じます。 
【問い合わせ先】 
厚生労働科学研究医療技術評価総合研究事業｢診療ガイドラインの評価に関する研究｣事務局 
国立保健医療科学院政策科学部長 長谷川敏彦 
Fax  ：048-468-7983（Tel：048-458-6178） 
Email：hasegawa@niph.go.jp  
【アンケート結果のご連絡先】 
アンケート結果をご希望の先生方にお送りさせていただきます。先生の Email アドレス、又は
Fax番号をご記入ください。 
Email:（               ）  Fax  :（               ） 
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Appendix 2. Survey questionnaire (2004) 
(Reprinted with permission of Toshihiko Hasegawa)
A. ガイドラインについてお聞きします。 
1．ガイドラインの存在や内容の認識、使用についてお聞きします。「はい」の場合は順に右へ進んで下さい。 
 1) あるのを知っている 2)内容を見たことがある 3) 内容を知っている 4) 使っている 
高血圧 1 いいえ  2 はい 1 いいえ  2 はい 1 いいえ  2 はい 1 いいえ  2 はい 
糖尿病 1 いいえ  2 はい 1 いいえ  2 はい 1 いいえ  2 はい 1 いいえ  2 はい 
喘息 1 いいえ  2 はい 1 いいえ  2 はい 1 いいえ  2 はい 1 いいえ  2 はい 
前立腺肥大症 1 いいえ  2 はい 1 いいえ  2 はい 1 いいえ  2 はい 1 いいえ  2 はい 
胃潰瘍 1 いいえ  2 はい 1 いいえ  2 はい 1 いいえ  2 はい 1 いいえ  2 はい 
腰痛症 1 いいえ  2 はい 1 いいえ  2 はい 1 いいえ  2 はい 1 いいえ  2 はい 
アレルギー性鼻炎 1 いいえ  2 はい 1 いいえ  2 はい 1 いいえ  2 はい 1 いいえ  2 はい 
高脂血症 1 いいえ  2 はい 1 いいえ  2 はい 1 いいえ  2 はい 1 いいえ  2 はい 
2．ガイドラインの内容を見たことがある方にお聞きします。どのようなところでご覧になりましたか。 
高血圧 1 学術誌 2 専門書籍 3 製薬企業パンフレット 4 ウェブサイト 5 その他（       ） 
糖尿病 1 学術誌 2 専門書籍 3 製薬企業パンフレット 4 ウェブサイト 5 その他（       ） 
喘息 1 学術誌 2 専門書籍 3 製薬企業パンフレット 4 ウェブサイト 5 その他（       ） 
前立腺肥大症 1 学術誌 2 専門書籍 3 製薬企業パンフレット 4 ウェブサイト 5 その他（       ） 
胃潰瘍 1 学術誌 2 専門書籍 3 製薬企業パンフレット 4 ウェブサイト 5 その他（       ） 
腰痛症 1 学術誌 2 専門書籍 3 製薬企業パンフレット 4 ウェブサイト 5 その他（       ） 
アレルギー性鼻炎 1 学術誌 2 専門書籍 3 製薬企業パンフレット 4 ウェブサイト 5 その他（       ） 
高脂血症 1 学術誌 2 専門書籍 3 製薬企業パンフレット 4 ウェブサイト 5 その他（       ） 
3．ガイドラインを知るには、どのような方法が便利でしょうか。便利と思われる順位をご記入ください。 
学術誌 専門書籍 製薬企業パンフ ウェブサイト ＣＤ－ＲＯＭ その他 
(  )位 (  )位 (  )位 (  )位 (  )位 (  )位(内容：        ) 
4．ガイドラインの内容を見たことがある方にお聞きします。ガイドラインをどう思われますか。 
 1) 内容が分かりやすい 2) 診療で使いやすい 3) 科学的根拠に基いている 
高血圧 1 はい 2 いいえ 3分からない 1 はい 2 いいえ 3分からない 1 はい 2 いいえ 3分からない 
糖尿病 1 はい 2 いいえ 3分からない 1 はい 2 いいえ 3分からない 1 はい 2 いいえ 3分からない 
喘息 1 はい 2 いいえ 3分からない 1 はい 2 いいえ 3分からない 1 はい 2 いいえ 3分からない 
前立腺肥大症 1 はい 2 いいえ 3分からない 1 はい 2 いいえ 3分からない 1 はい 2 いいえ 3分からない 
胃潰瘍 1 はい 2 いいえ 3分からない 1 はい 2 いいえ 3分からない 1 はい 2 いいえ 3分からない 
腰痛症 1 はい 2 いいえ 3分からない 1 はい 2 いいえ 3分からない 1 はい 2 いいえ 3分からない 
アレルギー性鼻炎 1 はい 2 いいえ 3分からない 1 はい 2 いいえ 3分からない 1 はい 2 いいえ 3分からない 
高脂血症 1 はい 2 いいえ 3分からない 1 はい 2 いいえ 3分からない 1 はい 2 いいえ 3分からない 
 
B．6つのガイドラインについてお聞きします。 
1．高血圧 
1)  2000年ガイドラインでは、かつて境界域であった 140～159/90～94mmHg も軽症高血圧に診断されることとな
り、全国で 1100万人が新たに高血圧患者となりました。この新定義について、妥当と思われますか。 
 
2) この軽症高血圧患者には食事や運動等の非薬物療法が薦められています。 先生はどう治療しておられますか。 
 
 
1 妥当  2 旧定義 160/90mmHg以上の方がいい 3 分からない 
1 自ら食事や運動指導を行っている 2 栄養士や保健師等を雇って指導させている 
3 自院ではできないので他院に紹介している 4 何も治療していない 5 投薬治療を行っている 90
2．糖尿病 
1)新ガイドラインでは「原因」と「病態」による分類の 2つが提示されています。どちらが良いと思われますか。 
 
2)  新ガイドラインでは血糖の管理を HbA1c値 5.8 以上 6.5%未満とすべきとしています。適切と思われますか。 
  
3．喘息 
ガイドラインでは、発作が出てから治療するよりも、普段から気道のピークフローを患者に測らせ、閉塞が認め
られると早めにステロイド吸入薬を使うことを勧めています。診療に使っておられますか。 
 
4．前立腺肥大症 
排尿障害症状（I-PSS、QOL スコア）排尿機能、前立腺容積に基づく重症度評価で、中等症の場合の薬物療法では
α遮断剤を第一選択として推奨していますが、妥当と思われるでしょうか。 
 
5．アレルギー性鼻炎 
2002年アレルギー性鼻炎ガイドラインでは、「くしゃみ・鼻水」と「鼻閉」型に分け、全く異なった治療法が薦め
られていますが、以前のように重症度別で 2つに分けない方法とどちらが良いと思いますか。 
 
6．高脂血症 
2002 年の定義で、高コレステロール血症の閾値は 220mg/dL となりました。一方で、240mg/dL 以上で脳卒中死亡
リスクが高くなることが報告されており、上げた方がよいとの意見もあります。どちらがよいと思われますか。 
 
 
C．ガイドライン全般についてお尋ねします。 
1．ガイドラインは医師の診断を支援するために作られるものですが、現場の治療に有用であると思われますか。 
 
2．1) 厚生労働省の研究費によってガイドラインが作成されていることについて、どのように思われますか。 
 
2) その理由は何ですか。 
 
 
3．どのくらいの頻度で改訂すべきですか。 
 
 
D．ご回答をいただく先生についてうかがいます。 
1．ご年齢        歳 
2．従事されている主な診療科１つに○をつけて下さい。 
1 内科     2 消化器科（胃腸科）    3 循環器科    4 呼吸器科    5 精神科   6 神経科（神経内科） 
7 心療内科   8 リウマチ科     9 アレルギー科    10 小児科     11 その他 (                  科) 
3．先生の外来での１日平均診察人数と、その中で各疾患の大よその割合をお教え下さい。 
1)  平均患者数  人／日 
2)  平均患者数に占める各疾患の患者数の大よその割合（例：1日 10人のうち高血圧患者が 2人の場合、20％） 
① 高血圧  ％ ② 糖尿病  ％ ③ 喘息  ％ 
④ 前立腺肥大症  ％ ⑤ 胃潰瘍  ％ ⑥ 腰痛症  ％ 
⑦ アレルギー性鼻炎  ％ ⑧ 高脂血症  ％    
1 有用である  2 有用でない  3 分からない  4 その 他（                ） 
1 良い     2 悪い     3 分からない  4 その 他（                ） 
 
 
1 上げた方がよい 2 このままでよい 3 分からない 
 
1 以前の方法がよい 2 このままでよい 3 分からない 
 
1  1年以上 2年未満毎  2  2年以上 5年未満毎  3  5 年以上毎  4 研究成果に応じて 
5 その他（         ） 
1 特定グループからの圧力がかかるべきでない   2 標準治療を政府は推し進めるべきである  
3  医療に政府は介入すべきでない 4 その他（                        ） 
 
 
1 上げた方がよい 2 このままでよい 3 分からない 
 
1 使っている   2 使っていない 
1 妥当  2 不適当である 3 分からない 
1 原因分類(1・2型/その他/妊娠糖尿病)   2 病態分類(正常/境界/糖尿病領域)   3 分からない 
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【参考資料】 
疾患名 ガイドライン名 作成年 作成機関 
厚生労働科学研究費
による支援の有無 
高血圧 高血圧治療ガイドライン 2000 日本高血圧学会 有 
糖尿病 
糖尿病診療ガイドライン 
（糖尿病４５巻 Supplement 1） 
2002 日本糖尿病学会 有 
喘息 喘息予防・管理ガイドライン 2000 
厚生省免疫・アレルギー
研究班 
有 
前立腺肥大症 
ＢＰＨ（前立腺肥大症）診療 
ガイドライン 
2001 
厚生労働科学研究「泌尿
器科領域の治療標準化に
関する研究班」（主任研究
者 大島伸一） 
有 
胃潰瘍 
ＥＢＭに基づく胃潰瘍診療 
ガイドライン 
2003 
科学的根拠（evidence）
に基づく胃潰瘍診療ガイ
ドラインの策定に関する
研究班 
有 
腰痛症 成人の急性腰痛治療ガイドライン 1995 AHCPR(現 AHRQ) 有 
アレルギー性
鼻炎 
鼻アレルギー診療ガイドライン 2002 
鼻アレルギー診療ガイド
ライン作成委員会 
一部あり 
高脂血症 動脈硬化性疾患診療ガイドライン 2002 日本動脈硬化学会 無 
 
ガイドラインに関するご意見をご自由にお書きください。 
 
 
ご協力ありがとうございました。 
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